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General Introduction 
The Guillain-Barre syndrome (GBS) is a monophasic (sub)acute inflammatory 
demyelinating predominantly motor polyradiculo-neuropathy. Clinical criteria 
have been proposed by Asbury (Asbury et aI., 1978; Asbury and Cornblath, 1990). 
GBS is a selflimiting disease, however, up to 30% of the patients may need 
temporary artificial ventilation; about 15% remain disabled and mortality is esti-
mated to be up to 5%. Therefore, GBS must be regarded as a serious disease. 
Plasma exchange (PE) and more recently high dose immune globulins ([vIg) have 
been proved to be succesful in shortening the duration of the disease, the duration 
of artificial ventilation and to improve outcome at 6 months (GBS study group, 19-
85; van del' Meche et aI., 1992; French cooperative group, 1992). In contrast to 
immune globulin therapy, plasma exchange is not always possible for haemodyna-
mic reasons. In addition it is generally not feasible in children, not in all hospitals 
available, and is in general rather cumbersome. Therefore in the multicentre Dutch 
Guillain-Barn: Study the effectiveness of immune globulins versus plasma exchan-
ge was evaluated in 150 patients, with a main aim to demonstrate at least equal 
efficacy. This study revealed therapeutic effectiveness of both therapies with a 
limited but significant superiority of immune globulins over plasma exchange (van 
del' Meche et aI., 1992). 
[n the Dutch Guillain-Barre trial each patient was tested electrodiagnostically three 
times in an early stage of the disease according to a rigid protocol. The results of 
these electro diagnostic studies are the subject of this thesis. 
Chapter one gives a review of the Guillain-Barre syndrome in particular with 
respect to symptoms and signs and the natural history of the disease. Also patholo-
gical, immunological and therapeutic features are reviewed briefly. 
Electrophysiological principles of nerve conduction in normal nerves and the 
electrophysiological features of demyelination are discussed in chapter two. They 
form the necessary background for the interpretation of motor conduction studies. 
According to these principles the protocol, which was designed for the present 
study, is presented along with the results of application in 45 healthy volunteers. 
The resulting limit values, applied in the present study are also presented. In chap-
ter three, the literature concerning the electrodiagnostic aspects of GBS since 1960 
is reviewed. [n chapter fOUl', electrodiagnostic findings in GBS patients in the 
Dutch GBS Study are described. Based on these results, the construction of 
electrodiagnostic criteria for polyneuropathy and for demyelination are worked out 
in chapter five. In chapter six the prognostic value of electrodiagnostic testing is 
described. Chapter seven describes aspects of axonal degeneration in the Guillain-
Barre syndrome. Finally, chapter eight concludes this thesis with a general discus-
sion and several suggestions for research in the near future. 
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Chapter one 
The Guillain-Barre syndrome: an introduction 
1.1 Terminology 
The Guillain-Barre syndrome is a (sub)acute inflammatory polyradiculoneuropathy 
of unknown etiology. This condition was first described by Landry in 1859 (Land-
ry, 1859) and Guillain, Barre and Strohl in 1916 (Guillain et aI., 1916) and hence 
sometimes called Landry-Guillain-Barre-Strohl syndrome. Today, the disease is 
generally reffered to as Guillain-Barre syndrome or acute inflammatory demyelina-
ting polyradiculoneuropathy (AIDP). 
1.2 Epidemiology, antecedent events 
True incidence in GBS probably varies in range from 1.5 to 2.0 cases per 100.000 
annually (Alter, 1990; Arnason, 1993). These incidences are fairly constant for 
different geographical regions over the world. GBS occurs at all ages with two 
minor peaks in frequency: in young adults and in the fifth through eighth decade 
(Kaplan et aI., 1983; Arnason, 1993). Most series have shown no seasonal 
preponderance to be present; usually GBS occurs sporadically but outbreaks have 
been reported (Arnason, 1993). In two thirds of the GBS patients an antecedent 
influenza-like syndrome with fever and in 10% to 20% an acute gastroenteric 
episode has been reported (Arnason et aI., 1993). Usually, Cytomegalo virus, 
Epstein-Barr virus, human immunodeficiency virus, Mycoplasma pneumonia, 
Campylobacter jejuni and other infections, but also surgery, vaccination and 
malignant disease have been linked to GBS (Arnason, 1993). One to three weeks 
after the prodromal phase the first symptoms appear. 
1.3 Signs and symptoms and natural history 
Fifty percent of the patients reach their point of maximum deficit (nadir) within 2 
weeks after onset and more than 80% respectively 90% within 3 and 4 weeks 
(Castaigne et aI., 1966; Masucci and Kurtzke, 1971; Loeffel, 1977; Ropper, 1991). 
In the acute phase up to 5% of the patients may die (Loeffel et aI., 1977; Ropper, 
1991). After the acute phase, a plateau phase follows, with an average duration of 
15 days (l - 90 days) and in 71% 2 weeks (Ropper, 1991). Recovery is slower than 
the initial deterioration and after 4 to 6 months 80% of the patients have recovered 
satisfactorely; further recovery may continue even up to 2 years in severely 
affected patients with extensive axonal degeneration. 
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Prominent symptoms are quadriparesis, usually starting in the legs, occasionally, 
however, the disease begins with facial diplegia. Sometimes proximal muscle 
groups are more affected, but later distal weakness will predominate. The distri-
bution of the weakness may be somewhat asymmetrical (Amason, 1993). Intercos-
tal and diaphramatic paresis may appear later in the disease. In at least 50% facial 
diplegia can be found. Oropharyngeal involvement may occur in 40% and may 
herald respiratory failure (Winer, 1985; Ropper, 1991). The external urethral 
sphincter is involved in 10% t020%, however, incontinence is usually caused by 
overflow as internal sphincter function is spared. In the past respiratory failure has 
been an important cause of death, but today it can be managed by artificial venti-
lation. Objective sensory loss is present in 75% and pain in 55% of the patients 
(Ropper, 1991). Autonomic involvement may occur in a variety of ways; cardio-
vascular dysautonomies account for half of the deaths in GBS (Keenlyside, 1980). 
Areflexia is not always present initially, although the reflexes become abolished in 
the course of the disease (van del' Meche et aI., 1988a). Fifteen percent of the 
patients are left with permanent residual deficits, ranging from footdrop to 
wheelchair bound status and 5% of the patients remain more or less severely 
disabled (Pleasure et aI., 1968; Winer, 1985; Ropper et aI., 1986). De Jager repor-
ted that only one third ofGBS patients, who needed artificial ventilation, recovered 
completely (De Jager, 1988). 
1.4 Clinical criteria 
Usually, the clinical diagnosis presents little difficulty. Several sets of criteria have 
been used in the past, particularly those of Masucci, Kurtzke and Ravn (Ravn, 
1967; Masucci and Kurtzke, 1971). Today's established set is from Asbury et al. 
(see appendix I) (Asbury et aI., 1978; Asbury and Cornblath, 1990). 
1.5 Pathology and immunology 
In the peripheral nerves of Guillain-Barre patients mononuclear cell infiltrates and 
segmental demyelination may be present throughout the whole extent of the nerve. 
Perivenular infiltrates of lymphocytes and macrophages are found. Areas of 
segmental demyelination are associated with lymphoid cellular infiltrates 
(Haymaker and Kernohan, 1949; Asbury et aI., 1969; Kanda et aI., 1989; Honavar 
et aI., 1991; Amason, 1993). Some nerves may be spared, for instance the sural 
nerve may lack cellular infiltrates (Brechenmacher et aI., 1987; Hughes et aI., 
1992; Brown, 1993). No predominant involvement of motor- over sensory roots 
nor predominance of proximal over distal segments has been found. In recent stu-
dies, however, possibly some preference for proximal segments, extreme distal 
nerve twigs and usual compression sites exists (Amason, 1993). The earliest 
change in the myelin sheath occurs paranodically, resulting in a widening of nodal 
gap. Demyelination progresses centripetally towards the center of the Schwan nee II. 
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A second site of myelin breakdown occurs at the Schmidt-Lanterman incisura. 
Secondary axonal degeneration may be seen. Axonal involvement, however, may 
be so severe, that it has been questioned whether a primary axonal form of GBS 
exists (Feasby et aI., 1986,1993; van del' Meche, 1991a, 1991b,1994; Dijck, 1993; 
Brown, 1993). In lesions, which are several days to several weeks old, proliferation 
of Schwann cells occurs along denuded axons and also at sites, where axonal 
degeneration had taken place. Each denuded internode is replaced by.several new 
thinner internodes. This process of repair begins already in the phase of demyeli-
nation (Amason, 1993). Because of the pathological changes and the fact that GBS 
usually occurs within one or two weeks after an infection it has been held for long 
to be an immune mediated disease. This has been supported by the study of experi-
mental allergic neuritis (EAN). Injection of crude myelin in combination with 
complete Freund adjuvant results in cell mediated demyelination in the rat and an 
antibody mediated demyelination in the rabbit. In the rat the glycoprotein P2 and in 
the rabbit galactocerebroside are identified as antigens. The same antigens are not 
or rarely involved in humane GBS (Hughes, 1991). Recently a pathological study 
has suggested, however, that in GBS in individual patients either a more cellular or 
more humoral mechanism may play a role (Honovar et aI., 1991). This 
pathological variability may be the basis for the clinical and physiological 
variability observed (van del' Meche et aI., 1988a). Detailed concepts of the 
immune mechanisms in GBS have recently been described (Hartung et aI., 1993; 
van del' Meche and van Doorn, 1994). Peripheral blood T-Iymphocytes expressing 
activation markers HLA-DR, the transferrin receptor and the membrane bound IL-
2 receptor are increased. Furthermore, macrophages are activated in the early part 
of the disease. The aforementioned cells are most likely involved in antigen 
presentation in inflammatory foci. In a proportion of patients antibodies against 
peripheral nerve constituents do occur in the acute phase of the disease (Domes et 
aI., 1991). In our patientgroup 30% were shown to have antibodies against the 
ganglioside GMI. Also it was shown that 36% of the patients had a preceding 
infection with Campylobacter Jejuni. Subsequently, it has been demonstrated, that 
molecular mimicri may exist between specific strains of Campylobacter bacteria 
and GMI ganglioside of the peripheral nerve (Oomes et aI., 1992). 
1.6 Therapeutic aspects 
Although the Guillain-Barre syndrome is a self limiting disorder, 10 - 25% of the 
patients require artificial ventilation and up to 5% of the patients may die. 
Therefore an effective therapy has been searched for. Corticosteroids were among 
the first drugs tested (Shy and McEachern, 1951). Later trials were performed with 
prednison (Swick and McQuillain, 1971; Hughes et aI., 1978). They did not result 
in a firm conclusion, but all studies had a small sample size. In a number of clinical 
trials the efficacy of plasma exchange has been evaluated (Greenwood et aI., 1984; 
Osterman et aI., 1984; GBS study group, 1985; French cooperative group, 1992). 
This therapy has proven to be effective in decreasing morbidity, including the 
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the duration of artificial ventilation and outcome at 6 months. As a result of the 
efficacy of high dose intravenous immune globulins in chronic inflammatory 
demyelinating polyneuropathy (ClOP) (Vermeulen et aI., 1985; van der Meche et 
aI., 1989), a pilot study was performed in the Guillain-Barre syndrome (Kleyweg 
et aI., 1988). The results suggested that this therapy might be effective in Guillain-
Barre syndrome. Immune globuline has several advantages over plasma exchange 
such as: general availability, few contraindications and easier management in 
children. For these reasons, the Dutch Guillain-Barre trial, a randomised multi-
center study, comparing the effectiveness of intravenolls immune globulin and 
plasma exchange in Guillain-Barre syndrome was performed. The main conclusion 
of this study was that in the acute Guillain-Barre syndrome, treatment with 
intravenous immune globulin is at least as effective as plasma exchange and may 
be superior (van der Meche et aI., 1992). The major part of the EMG results are 
from patients in this study and a summary of the design of the trial is given below. 
1.7 The Dutch Guillain-Barre trial 
1.7.1 Entry into the trial 
Patients were eligible if they fullfil led the criteria for acute Guillain-Barre 
syndrome (Asbury et aI., 1978; Asbury and Comblath, 1990), were not able to 
walk 10 meter independently, and could enter the study within two weeks of onset 
of neuropathic symptoms. The criteria for exclusion were: age less than four years, 
a previous period of Guillain-Barre syndrome, a previous severe allergic reaction 
to properly matched blood products, known selective 19A deficiency, pregnancy, 
treatment with immunosuppressive agents, severe concurrent other disease, or 
unavailability for follow-up during the next six months. Hereafter, randomisation 
for treatment was performed. 
1.7.2 Treatment 
After randomisation to plasma-exchange treatment was started as soon as possible; 
it was aimed to exchange 200 to 250 ml plasma per kilogram of bodyweight in five 
sessions within 7 to 14 days. Intravenous immune globulin was given during five 
subsequent days in a dose of 0.4 gram per kilogram bodyweight per day. 
1.7.3 Assessment of motor function 
The degree of motor function was expressed on a seven point functional scale used 
in previous trials, on which 0 denotes healthy; I, having minor symptoms and signs 
but fully capable of manual work; 2, able to walk > ~ 10 III without assistance; 3, 
able to walk > ~ 10 m with a walker or support; 4, bedridden or chairbound 
(unable to walk 10 m with a walker or support); 5, requiring assisted ventilation for 
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at least part of the day; and 6, dead (Greenwood et aI., 1984; Guillain-Barre study 
group et aI., 1985). 
1.7.4 Follow-up schedule 
This functional score was measured at study entry and 16 times during six months 
of follow-up: 3 times a week during weeks 1 and 2, once a week through week 6, 
and in weeks 8,10,14,18,22 and 26. Of a total of 193 patients 150 patients entered 
the study from June 1986 through December 1989. Three of the 150 randomised 
patients proved to be ineligible soon after randomisation and were withdrawn from 
the study (unstable angina pectoris, transverse myelitis, Miller-Fisher syndrome). 
73 patients underwent plasma exchange and 74 received immune globulin; their 
respective mean ages were 48.8 ± 19.2 and 46.2 ± 19.3 years. 
1.7.5 Results 
In the plasma-exchange group, 34 percent of the patients improved by one or more 
functional grades after four weeks, as compared with 53 percent in the immune 
globulin group; a difference of 19 percent (99 percent confidence interval, -2 
percent to 39 percent; 95 percent confidence interval, 3 percent to 34 percent; P = 
0.024). Hence it was concluded, that immune globulin was not only as effective as 
plasma exchange but that significantly more patients in the immune globulin group 
reached the main outcome measure of an improvement with one or more grades on 
the functional scale at four weeks after randomisation (van der Meche et aI., 1992). 
1.7.6 Electrodiagnostic studies 
The Dutch Guillain-Barre study resulted in the availability of a large group of 
clinically well defined Guillain-Barn, patients. The follow-up period of 6 months 
substantiated the clinical diagnosis further. Therefore this study was an unique 
opportunity to study the electrodiagnostic features of the disease. Three subsequent 
EMGs were performed at the time of randomisation and one and four weeks later. 
Electrodiagnostic testing was performed in temperature controled rooms or 
intensive care units, using standardised conventional techniques. Once the 
electrodiagnostic testprotocol had been designed, it was discussed with all 
participating centers before the trial was started (appendix II). Results were put on 
standardised data forms and sent to the study group coordination centre (appendix 
III). All tests were done by experienced clinical neurophysiologists, all members of 
the Dutch Guillain-Barre Study Group (appendix IV). 
The following topics are the main aims of this thesis: 
1. the description of electrodiagnostic findings in GBS in an early stage of the 
disease and the search for electrophysiological subtypes; 
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2. the construction of electrodiagnostic criteria for polyneuropathy and de-
myelination; 
3. the evaluation of the prognostic value ofelectl'Odiagnostic testing; 
4. the study of axonal degeneration in Guillain-Barre syndrome. 
Chapter two 
The technique and interpretation of motor nerve 
conduction studies 
2.1 Electrophysiological aspects of nerve conduction in normal and in abnormal 
nerve fibers 
The principles of the electrophysiology of normal conduction in myelinated fibers 
have been extensively elaborated in the past (Tasaki, 1953; Hodgkin, 1964; Katz, 
1971; Keynes and Aidley, 1981; Kuffler et aI., 1984; Kandel and Schwarz, 1985). 
A brief summary is given here. 
At rest, an intracellular membrane potential of -60 m V with respect to the extracel-
lular environment exists. This is maintained by an active process, whereby intracel-
lular sodium is exchanged for extracellular potassium. This results in a relatively 
high intracellular concentration of potassium and a relatively low intracellular 
concentration of sodium relative to the extracellular environment. The membrane 
potential may change because of the presence of voltage dependent ion-channels, 
specifically permeable for these ·ions. At the node of Ranvier a high ~ensity of 
sodium channels and a natural lack of myelin exists: therefore the axon is only 
permeable for sodium-ions at this site of the myelinated axon. Ifat this site a depo-
larisation occurs beyond a certain threshold, voltage dependent sodium ion-chan-
nels will open. Because of the natural electro-chemical gradient, sodium ions will 
enter the cell. Being an influx of positive charge, further depolarisation and, in 
turn, further opening of voltage dependent sodium channels will result. The net 
effect is an explosive influx of sodium ions and a subsequent reversal of the polari-
ty of the membrane potential: the action potential. This process comes to an end 
when a new equilibrium has been reached (+55 m V). At this point, sodium chan-
nels will close and potassium ion channels will open. The result is a restoration of 
the initial resting membrane potential. In this way the cycle of the action potential 
is completed. Due to this process an internal longitudinal current of positive charge 
is generated along the membrane. This positive current will decrease adjacent 
membrane potential and has therefore a depolarising effect. The current flows back 
via the external longitudinal current (local circuit). Normally, the internal longitu-
dinal current is strong enough to depolarise the next node beyond the threshold for 
the generation of a new action potentiaL Even over a distance of two or three nodes 
a new action potential can be gel1erated. The same cycle is repeated subsequently 
node after node. A jump like process is the result, the so called saltatory conduc-
tion, which is the hallmark of conduction in myelinated fibers. The latency, with 
which action potentials are generated from one node to the next is called the inter-
nodal conduction time, which determines the conduction velocity of a fiber. Inter-
nodal conduction time is proportional to the speed with which the internal longitu-
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dinal current generated at one node has reached the threshold for action potential 
generation at the next node. The initial speed will be determined by the action 
potential rise time, which is a function of sodium ion channel kinetics in the nodal 
membrane. Furthermore, at the nodal membrane high membrane capacitance, low 
transmembrane resistance, and high intra-axonal resistance will diminish the speed 
(time constant) and the reach (length constant) of the depolarising effects of the 
internal longitudinal current. Low nodal membrane capacitance and high trans-
membrane resistance due to myelin are natural characteristics of myelinated fibers. 
They result in shorter internodal conduction time and hence in a high conduction 
velocity as well in a high safety factor. Large diameter fibers will have the fastest 
conduction, because of a smaller intra-axonal resistance. Obviously, changes in 
nodal as well as in internodal properties will have influences on conduction proper-
ties. Temperature has substantial effects on conduction, because it affects action 
potential generation. In particular, the rise time and duration of the action potential 
both decrease if the temperature of the nerve surrounding is higher. This results in 
a decrease of internodal conduction time and in decrease of the safety factor. 
Several decades ago, biophysical models have been developed for the description 
of action potentials as well as for conduction in normal nerve fibers (Hodgkin et 
aI., 1952; Frankenhauser and Huxley, 1964; Rosenfalck, 1969). 
Historically, Erb was the first to detect complete block in human traumatic 
peripheral nerve lesions using electrical stimuli. Muscle twitches could be obser-
ved by electrical stimulation of the nerve distal to the lesion but not proximal (Erb, 
1876). Gombault decribed in 1881 segmental demyelination resulting from local 
traumatic lesions in man (Gombault, 1881). 
However, the first systematic observations on conduction block in experimentally 
induced demyelination in cats -by local nelve compression- were done in 1944 
(Denny-Brown and Brenner, 1944a, 1994b). 
Tasaki induced demyelination by the application of saponin (a lipid solvent) to a 
single internode preparation of frog peripheral nerve. This resulted in an increase 
in internodal conduction time, which evolved in conduction block within 20 minu-
tes. In addition, the specific electrical properties of the demyelinated internodal 
membrane could be derived. Compared to normal membrane increased capacitance 
and decreased transmembrane resistance were found (Tasaki, 1955). These experi-
ments can be regarded as the first biophysical approach of the consequences of 
demeylination. 
Local demyelination can be achieved by administration of diphteria toxin in the 
cat. In this way McDonald (1963a, 1963b was able to demonstrate conduction 
block as well as conduction slowing in whole nerve preparation from the recording 
of the compound nerve action potential, representing activity of a large number of 
fibers. Also in experimental allergic neuritis models, in which demyelination was 
induced by immunisation, it was possible to show these effects (Waksman et aI., 
1955; Keaser et aI., 1962; Cragg and Thomas, 1964; Hall, 1967a, 1967b). 
In experimentally induced focal demyelination resulting from direct micro-injec-
tion of diphteric toxin in the cat dorsal column, it was found that normal conduc-
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tion on either side of stretches of demyelination were present and also that conduc-
tion can persist through smaller lesions, albeit with lower velocity (McDonald and 
Sears, 1970). 
Rasminsky et al. were able to make a detailed study of internodal conduction 
between successive nodes of Ranvier in undissected spinal root fibers of the rat 
demyelinated by anti-galactocerebroside serum. They found that internodal 
conduction time may be increased up to 25 times of normal before conduction 
block occurs. This may be due to increased membrane capacitance and decreased 
transmembrane resistance, which both have an impeding effect on internallongitu-
dinal current. Therefore, the depolarisation, which occurred at the next node of 
Ranvier was held to be insufficient to reach the threshold for the generation of an 
action potential (Rasminsky and Sears, 1972). These effects were found to be 
heavily dependent on temperature (Rasminsky, 1973), causing reversible conduc-
tion block in demyelinated fibers with small increases in temperature. Later, the 
introduction of electronic averaging techniques allowed the discovery of continu-
ous conduction in completely demyelinated fibers accompanied by extremely slow 
conduction (Bostock and Sears, 1976, 1978; Bostock, 1993). 
Saida and Sumner introduced acute antibody mediated conduction block in peri-
pheral nerve fibers in the rat after intraneural injection of serum from galactoce-
rebroside hyperimmunised rabbits (Saida et aI., 1979, 1980; Sumner, 1981). Simi-
lar effects were found with serum from some GBS patients in some studies, but not 
in all (Stllnner et aI., 1982; Oomes et aI., 1992). [n an experiment performed by 
Lafontaine in rat single root fibers with anti-galactocerebroside serum, it was found 
that internodal conduction time and conduction block was associated with an 
increased nodal capacitance. Therefore they concluded, that acute conduction 
block in this model was due to pat'anodal demyelination (Lafontaine et aI., 1982). 
This was in fact already predicted by computer simulation by Koles (Koles and 
Rasminski, 1972). Conduction block occurred earlier in smaller fibers (Sumner, 
1981; Lafontaine et aI., 1982).lt was suggested that effects on conduction proper-
ties of the increased ratio of nodal to internodal capacitance would be greater in 
smaller fibers compared to larger diameter fibers. 
Remyelination was extensively studied by Smith in Iyso-phosphatidylcholine 
induced demyelination. Remyelination was accompanied by restoring of the nor-
mal safety factor and by near normal nerve conduction velocities. The newly 
formed internodal distances were shorter and the myelin sheats were thinner and 
therefore the transmembrane resistance lower (Smith and Hall, 1980; Bostock et 
aI., 1981). Before remyelination, continuous conduction was followed by the 
development of node like patches along the demyelinated axon membrane, the so 
called phi-nodes (physiological nodes). They occured in the absence of remyeli-
nation 4 days after induction of the lesion (Smith et aI., 1982a, 1 982b). The pheno-
menon of phi-nodes has also been described by Feasby in regenerating small axons 
(Feasby et aI., 1981). It is generally thought that this may represent regrouping of 
sodium channels (Smith et aI., 1982b). 
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Conduction block is the most impOliant consequence of demyelination. It may 
cause paresis and hypaesthesia. Demyelination may also result in ephaptic trans-
mission and in spontaneous impuls generation. This may result in paraesthesia, 
dysaesthesia or even pain if present in sensory fibers and in fasciculations and 
myokymia if present in motor fibers. Other consequences of demyelination include 
increased internodal conduction time and continuous impulse propagation, both 
resulting in conduction slowing as well as reduced ability to transmit a train of 
impulses (Rasminsky and Sears, 1972; Smith and Hall, 1980; McDonald et aI., 
1982), which may also add to paresis. Conventional electrodiagnostic studies can 
only reveal conduction slowing and conduction block. Advanced techniques are 
necessary to detect spontaneous impulse generation (Hagbart, 1979). 
2.2 Technique and interpretation of motor nerve conduction studies 
Introduction 
Motor nerve conduction studies are helpful in the diagnosis of peripheral neuropa-
thies. They have become even more impOliant now several demyelinating 
polyneuropathies such as Guillain-Barre syndrome, chronic inflammatory demyeli-
nating polyneuropathy and multi focal motor neuropathy (MMN) can be treated by 
immunomodulating therapies like IvIg, PE, corticosteroids and cytotoxic drugs 
(Guillain-Barre syndrome Study Group, 1985; Vermeulen, 1985; Pestronk et aI., 
1988, 1990; van Doorn et aI., 1990, 1991; Nobile Orazio et aI., 1990a, 1990b; 
French cooperative group, 1992; van der Meche et al. 1992). It is the only method 
to discriminate between motor neuron disease and MMN with persistent conducti-
on block, the distinction of which has obvious implications for management (Le-
wis et aI., 1982; Pestronk et aI., 1988; Nobile Orazio et aI., 1990a). However, 
limiting nerve conduction studies to the measurement of nerve conduction veloci-
ties, may erroneously suggest normal nerve function. It is a well known fact, that 
quadriparetic Guillain-Barre patients may show normal conduction velocities 
(Lambert, 1960; Brown and Feasby, 1984; Albers, 1985; Ropper, 1991). As will 
be elaborated below this is mainly due to the fact that blocked fibers may go unde-
tected with this approach. Motor nerve conduction studies may, however, be 
extended by simple measurement of amplitude and duration of the responses in 
order to obtain more information about nerve function, particularly conduction 
block and abnormal dispersion (Lambert, 1960; Sumner, 1981; Brown et aI., 1981; 
Brown and Feasby, 1984; Brown, 1984; van der Meche, 1988a; Brown and Bol-
ton, 1993). This chapter introduces the electrophysiological background of motor 
nerve conduction studies. The technique and interpretation of motor nerve 
conduction studies and in particular CMAP measurement, will be discussed. The 
application in several specific polyneuropathies will be reviewed and a protocol for 
further studies will be proposed. 
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2.2.1 Electrophysiological background of motor nerve conduction studies 
After stimulation of a motor nerve, contraction of the appropriate muscle will 
occur. If electrodes are attached to the skin over the muscle belly a Compound 
Muscle Action Potential (CMAP) can be recorded (fig. la). The CMAP is the 
summation of motor unit potentials (MUP's) generated by, numerically few, large 
motor units of which the axons are synchronically activated by the stim,!lus 
(Brown et a!., 1984). However, despite the fact that nerve fibers are activated in a 
synchronised manner, there is no such strict synchrony of the generated respective 
MUPs, because of differences in conduction velocity of the individual nerve fibers. 
In addition, differences in latencies are also due to the fact that, motor end plates 
are not in line, but, instead are scattered with regard to the recording electrode. As 
a result, electrical positive phases of one MUP will occur at the same time as 
negative phases of another MUP. The net effect is that a number of MUP's will 
cancel out each other, because of summation of electrical positive and negative 
phases. Because of this phase cancelation the CMAP is not simply the algebraic 
summation of all positive and negative phases of the MUP amplitudes (fig. Ib). 
Phase cancellation will be more pronounced if the distance between stimulation 
site and muscle increases, because naturally occurring differences in conduction 
velocities will augment the shift of MUPs in time. This effect is called temporal 
dispersion (fig. Ic) and is even stronger in sensory nerve compound action potenti-
als due to the very short duration of the sensory fiber potential compared to the 
MUP (Kimura et a!., 1986, 1988). Several authors regard a CMAP amplitude 
reduction up to 50% in the segment of the forearm due to phase cancellation possi-
ble in healthy individuals. Therefore, they advocate the use of CMAP area as a 
parameter, since this parameter shows less but still considerable reduction in 
healthy individuals (fig. Ib) (Kimura et a!., 1986; Kimura, 1988; Rhee et a!., 
1990). 
CMAP configuration is further influenced by motor end plate function and muscle 
fiber architecture. Also it is impoliant to realise that MUPs generated further away 
from the recording electrode will contribute less to the CMAP compared to nearby 
MUP's. Therefore, the CMAP amplitude is only an indirect indicator for the num-
ber of functionally intact nerve fibers between stimulation site and the muscle 
recording site. However, if a motor nerve is stimulated at several sites along its 
length, CMAP amplitudes evoked at more proximal sites will decrease only with a 
small percentage as is evident from observations in most healthy individuals (fig. 
2a)(see reference values in appendix V). Therefore this technique is very efficient 
in testing the integrity of the motor nerve over considerable distances of the perip-
heral nerve. 
The onset latency of the CMAPs is used for computing motor nerve conduction 
velocity (fig. I b). Onset, however, represents only the fastest conducting motor 
fibers. Nerve conduction velocity computed in this way is therefore "the maximal 
conduction velocity" and, as a consequence, many fibers in a nerve may become 
slowed without any effect on the maximal conduction velocity as long as the 
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fastest fibers remain intact. To overcome this limitation one may measure the 
degree of dispersion - i.e. the duration of the negative phase - of the CMAP (see 
below). 
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Fig. I. Summation ofMUPs into the CMAP. 
Diagram of peripheral motor nerve stimulation with resuiting CMAP. Each of the 8 hori-
zontal lines represent a large group of motor axons, innervating the muscle. Above the 
muscle, surface electrodes are attached in the "tendon-belly montage" and are connected to 
the recording apparatus at the right hand side. The vertical arrow indicates the stimulus site. 
a. Summation of MUPs into a CMAP. MUPs with similar configuration cause no phase 
cancellation and resuit in an unrealistic CMAP configuration with high amplitude and 
small duration. 
b. MUPs with characteristic diverse configuration cause phase cancellation and result in a 
more realistic CMAP configuration with lower amplitude and larger duration. CMAP 
parameters: onset latency; amplitude; surface of negative part; duration of negative part 
ofthe CMAP are indicated. 
c. as in h. with more proximal stimulation. As a consequence of normally occurring diffe-
rences in NCVs of different motor axons, the generation of MUPs is less synchronised, 
which resuls in a lower and broader CMAP configuration, compared to distal stimulati-
on. CMAPs ofb. and c. are shown in superposition. 
2.2.2 Effects of demyelination and axonal degeneration on motor nerve con-
duction 
Abnormal results in conduction studies may be caused by damage to myelin sheath 
or axon. Although these phenomena tend to occur simultaneously, we will discuss 
the effects separately. 
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2.2.2.1 Abnormalities of the myelin sheath 
The physiological consequences of demyelination are primarily conduction block 
and conduction slowing (Lambert, 1960; McDonald, 1963b; Sumner, 1981; Lafon-
taine et aI., 1982; Brown et aI., 1984; Feasby et aI., 1985; Albers et aI., 1985; 
Albers and Kelly, 1989) . 
Conduction block between stimulation site and muscle in a number of fibers will 
result in a decreased CMAP amplitude on stimulation proximal of the lesion (fig. 
2b). A normal CMAP may still be obtained on stimulation distal of the lesion. 
Stimulation proximal of the lesion in case of conduction block in all fibers will not 
give any response (fig. 2c). In contrast, if the axons are injured e.g. by transsection 
axons in the distal stump can be normally activated initially (fig. 2d). In a period of 
days, neither stimulation distally nor proximally will cause a response, because all 
nerve fibers distal to the lesion have undergone Wallerian degeneration and are not 
excitable anymore (fig. 2e). 
If demyelination and thereby conduction block is diffusely present over the length 
of a nerve, CMAPs become progressively smaller with more proximal stimulation 
(fig. 21). This may be a typical finding in some patients with acquired demyelinat-
ing polyneuropathy as in GBS and ClOP. The essence is, therefore, that stimula-
tion distal to a demyelinating lesion gives a normal response, whereas stimulation 
proximal to the lesion produces a decreased response in the muscle. Because the 
CMAP is the only means to detect conduction block, it is obvious that meticulous 
testing ofCMAPs is essential to the diagnostic evaluation of neuropathies. 
Slowing o/nerve conduction can be the result of different pathophysiologic mecha-
nisms as reviewed by Waxman (Waxman, 1977, 1980). In saltatory conduction, 
the action potential jumps from node to node. The time needed is called the inter-
nodal conduction time. In addition, the time needed for action potential generation 
at a node also adds a certain delay. As a consequence, the internodal conduction 
time, as well as the number of nodes passed by the action potential, will determine 
the final conduction velocity of a fiber. Internodal conduction time is prolongued 
and finally blocked by less efficient nodal depolarisation. This may be due to 
decreased resistance at the internode and increased capacitance at the node caused 
by internodal and paranodal demyelination. In complete demyelination the now 
continuous propagation will result in a very slow conduction. Conduction slowing 
in patients, recovered from a neuropathy, is probably best explained by an increase 
in the number of Ran vier nodes after remyelination. 
After repeated de- and remyelination, nerve conduction velocities of individual 
nerve fibers within a nerve may diverge widely. This causes abnormal temporal 
dispersion in MUP latencies after stimulation of the nerve and results in a longer 
duration of the CMAP waveform. In addition, the resulting increase in desyn-
chronisation of the constituent MUPs of the CMAP will result in an increase in 
phase cancellation, so, in turn, the amplitude of the CMAP will decrease. As this 
phenomenon will be stronger with more proximal stimulation, it may simulate 
conduction block. However, in contrast to CMAP reduction by conduction block, 
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Fig. 2. Effect of conduction block, axonal degeneration and reinnervation on configuration 
of distal and proximal elicited CMAPs. 
Diagram as in fig. 1. Arrows 1 to 4 represent progressively more proximal stimulation. At 
the righthand side the respective motor responses (CMAPs) shown in superposition. The 
CMAP resulting from most proximal stimulation is at the far right. Hatches indicate COI1-
duction block. Dashed lines indicate axonal degeneration; short dashes indicate reinnervati-
on. The vertical bar represents a transection. 
a. normal nerve conduction: slight CMAP reduction after more proximal stimulation due to 
normal temporal dispersion; 
b. focal partial conduction block: lower CMAPs on stimulation proximal of the lesion; 
c. focal complete conduction block (neurapraxia): total abolished CMAPs proximal of the 
lesion; 
d. transection (neuronotmesis): normal CMAPs distal to the lesion; 
e. transection with completed Wallerian degeneration in the distal stump (after 5 days): 
abolished CMAPs on any stimulation site; 
f. diffuse conduction block: length dependent CMAP amplitude reduction as may occur in 
GBS; 
g. axonal degeneration as in axonal neuropathies: low CMAP amplitudes on any stimula-
tion site; 
h. reinnervation as in traumatic nerve injuries: low polymorph CMAPs. 
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abnormal temporal dispersion will also cause a broad CMAP waveform (fig. 3). To 
estimate conduction block it is, therefore, important to appreciate CMAP duration. 
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Fig. 3. Abnormal temporal dispersion. 
As a consequence of nonRuniform conduction slowing in several motor axons some MUPs 
are very delayed (traces 4, nl. This results in an abnormal low and broad CMAP waveform 
as compared to the CMAP in the normal situation. More proximal stimulation further 
augments this phenomenon. 
A rather uncommon, but important finding in some polyneuropathies is a changed 
electrical excitability. Fibers, that are conducting normally may in these cases be 
difficult to stimulate electrically. This phenomenon is probably best explained by 
interstitial edema in the nerve or by changes in the myelin architectnre. Decreased 
CMAP amplitnde due to hypoexcitability may form a pitfall, that can be checked 
for by sufficiently increasing stimulus strength. This will result in the recruitment 
of more fibers and hence in increased CMAP amplitnde. In our experience decrea-
sed electrical excitability occurs frequently in chronic demyelinating neuropathies. 
2.2.2.2 Abnormalities of the axon 
After section of a nerve, conduction is abolished distally of the lesion due to Wal-
leI' ian degeneration, however, it will take approximately five days before this 
process is completed (Chaudry et aI., 1992). Therefore conduction studies can only 
distuingish axonotmesis and conduction block only after a 5 day interval (fig. 2d 
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and 2e). In axonal neuropathy, nerve conduction velocities are often preserved or 
found to be slightly diminished only. It is explained by the fact that"some of the 
thick fast conducting axons may be preserved. Slowing of conduction will occur, if 
thick axons are lost or have become thinner by atrophy (Waxman, 1977, 1980). 
Since in axonal polyneuropathy motor units are lost, the CMAP amplitude will be 
lower than normal, independent of the level of stimulation along the nerve (fig. 
2g). After regeneration and reinnervation, particularly in case of traumatic nerve 
injuries, axons may be very thin and as a consequence, conduction may be very 
slow, leading to excessive dispersion. This in turn causes phase cancelation and the 
result will be a low and irregular CMAP wave form (fig. 2h). 
In conclusion, by studying CMAP related parameters (amplitude and duration), 
conduction velocity and excitability, nerve conduction properties can be characteri-
sed. By stimulating the nerve at several sites along its length, it is possible to test 
different nerve segments for conduction properties. The use of these variables as 
guidelines for electrodiagnostic evaluation in polyneuropathy are proposed. Limit 
values were obtained in 45 healthy volunteers (appendix V). In the next section, 
we will briefly discuss the technique and interpretation of electrodiagnostic fin-
dings. 
2.2.3 Technique and interpretation 
2.2.3.1 CMAP amplitudes 
Nerve conduction studies are performed using surface electrodes in the "tendon-
belly montage", attached over the muscle belly. In this setting it is possible to 
search with the active electrode for the position in which an optimal CMAP can be 
obtained from the muscle innervated by the nerve in study (fig. 4A,I). The CMAP 
then shows the maximal amplitude, steepest and initial negative deflection and 
smallest duration of its negative phase as possible. One has to be alert for electrical 
shortcuts between the electrodes by electrode paste, for this lowers the recorded 
CMAP dramatically (fig. 4A,2). This approach may seems tedious, but significant 
changes in CMAP configuration with more proximal stimulation may offer impor-
tant diagnostic clues. 
If similar lolV CMAP amplitUdes are found ajler distal and proximal stimulation of 
the nerve one has to check first for inappropriately placed electrodes or electrode 
artifacts such as moist bridges (fig. 4A). If the CMAP amplitude grows further 
after increasing stimulus strength above usual levels, incorrect stimulus position is 
possible and searching for the optimal stimulus site by shifting the stimulating 
electrodes is necessary (fig. 4A,3). If a number of fibers have a higher stimulus 
threshold, this population will not be activated with the usual stimulus strength. 
This will also result in a lower CMAP but is not caused by conduction block or 
fiber loss (see below). If artifacts are ruled out and the nerve does not show signs 
of lesser excitability, lower CMAPs may point to axonal degeneration (amyotro-
phic lateral sclerosis (ALS), radiculopathies, axonal neuropathies) (fig. 4B,I), very 
distally located demyelination (e.g. demyelinating neuropathy) (fig. 4B,2) and 
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neuromuscular transmission block (Eaton-Lambert syndrome) (fig. 4B,3). Caution 
is necessary in interpreting absolute values as normal ranges may be quite broad, 
for instance the normal range for hypothenar CMAPs is 15 m V to 30 m V. 
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Fig. 4. Causes of low CMAP amplitudes. 
Causes of low CMAP amplitudes include artifacts (A I. inappropriately placed recording 
electrodes; A2. moist bridges; A3. inappropriately placed stimulus electrodes) and 
pathophysiological factors (BI. axonal degeneration; B2. distal condnction block; B3. 
Eaton-Lambert syndrome; B4. decreased excitability). 
If a higher CMAP is/ound ajlerproximal stimulation anomalous innervation has to 
be ruled out. A well known example is an accessory peroneal nerve to extensor 
digitorum brevis muscle. Another pitfall may occur if more than one nerve is 
activated at sites where nerves are not far apart as in the bicipital sulcus or at the 
wrist. The recording electrodes can then unintentionally be influenced by a CMAP 
from another muscle. A higher and changed CMAP waveform after proximal 
stimulation is very suspect for these phenomena. 
If CMAP amplitudes are lower ajler proximal stimulation several possibilities have 
to be considered before concluding that it is caused by conduction block. Anoma-
lous innervation, for instance median to ulnar (Martin-Gruber) anastomosis may 
also be an underlying cause (Oh, 1992) . Several strategies are possible to rule this 
out (Kimura, 1984, 1989). In anomalous innervation CMAP waveforms change 
after proximal stimulation as compared to distal stimulation. Another cause of errol' 
may be a shifted recording electrode position induced by movements during 
successively more proximal stimulation. This can easily be checked by repeating 
the distal stimulation and comparing it with previous results. Finally one has to be 
sure that the stimulus strength was really supramaximally, since more proximally 
the nerve may be burried deeper in the tissue. 
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Conduction block and temporal dispersion 
If, in distal to proximal CMAP amplitude reduction, anomalous innervation has 
been ruled out and the nerve has been stimulated supramaximally, conduction 
block in the nerve segment between distal and proximal stimulation sites is very 
probable (fig. 2b). It is important to search for focal conduction block outside usual 
compression sites in a patient suspected of motorneuron disease, since this is the 
only method to discriminate from multifocal motor neuropathy, which needs an 
essentially different clinical strategy. 
Amplitude reduction in the absence of conduction block will occur if abnormal 
strong phase cancellation is present. This effect may be suspected if the duration of 
the CMAP is abnormally increased with more proximal stimulation compared to 
distal stimulation. This is called temporal dispersion. This will lead to broad, poly-
morfand low CMAP waveforms, which can be easily recognised (fig. 3b). 
It is not always possible to separate conduction block from phase cancellation as a 
cause of CMAP amplitude reduction. It is, however, important to state here, that 
both conduction block and differential temporal dispersion are phenomena related 
to demyelination; for diagnostic purposes it is not necessary to distinguish between 
the two. Only conduction block, however, is related to clinical deficit (van der 
Meche et aI., 1989) . An attempt to distinguish between the two was made by 
Brown and Feasby (Brown and Feasby, 1984) . They suggested that if amplitude 
reduction exceeds 20% and if increase of duration of the negative phase of the 
CMAP does not exceed 15%, the amount of interphase cancellation is supposed to 
be small and the presence of conduction block is more likely the cause of CMAP 
amplitude reduction. In contrast if duration of the CMAP increases more then 15% 
with proximal stimulation, then amplitude reduction by interphase cancellation 
cannot be distinguished from conduction block. Several sets of electrodiagnostic 
criteria for primary demyelination have been constructed in recent years (Albers 
and Kelly, 1989; Barohn et aI., 1989; Asbury and Cornblath, 1990). 
2.2.3.2 Nerve conduction velocities (m-NCV) and distal motor latencies (DML) 
Conventionally, m-NCVs are computed by dividing the distance between sites of 
stimulation with differences in CMAP onset latency. Onset latency, however, is the 
earliest component of the CMAP, which is elicited by the fastest conducting motor 
fibers. Therefore, only the so called maximal m-NCV (usually just called m-NCV) 
can be obtained, which represents obviously only a smal contingent of motor units. 
Distances between stimulus sites at the skin are measured using a measuring tape 
or a pair of calipers. However, these points do not necessarily correspond with the 
site where the nerve fibers are actually depolarised (the so called virtual cathode). 
Moreover, additional inaccuracies in measuring distances will occur with deeply 
sited nerves with winding stretches, as for instance in the radial nerve across the 
spiral groove. 
Lower temperature of the nerve surrounding will cause a decrease in NCV. To 
minimise unwanted bias in conduction velocity from variation of temperature, one 
option is to warm up the limbs up to 30· Celsius. However, it is not always possi-
ble to apply this cumbersome procedure, particularly in the intensive care unit. 
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Other approaches are transforming measured values (distal motor latency and 
NCV) for a deviation of the standard temperature of35' Celsius or to apply limits 
of normal dependent on temperature. In our laboratory, we prefer transformation of 
DML and NCV values, because skin temperature corresponds well with nerve 
temperature (Dejesus et aI., 1973; Geerlings and Mechelse, 1985). Warming of the 
limb will certainly cause an increase of nerve temperature, however only after an 
unknown interval, which may introduce unpredictable results. 
Conduction slowing can be caused by several different mechanisms due to changes 
in architecture of myelin sheath or axon membrane. Examples in demyelination 
are: increased internodal conduction time, continuous conduction and an increased 
number of shorter internodes. An example of axonal causes is reduction of axonal 
diameter in atrophy. 
Hence, conduction slowing is a rather unspecific indicator of nerve dysfunction. 
Only a strong reduction in m-NCV (more then 70%) is a generally accepted clJa-
racteristic of demyelination (Lambert, 1960; McDonald, 1963b; Kelly, 1983; 
Albers et aI., 1985; Albers and Kelly, 1989; Brown and Bolton, 1993). 
Motor-NCVs do not necessarilly correlate with clinical motor status because weak-
ness is either caused by conduction block or axonal loss. Striking examples of the 
discrepancy between slow conduction and clinical deficit came from demyelinating 
polyneuropathies. In the acute GBS often near normal NCVs are present in quadri-
paralytic patients, because of a small number of still normally conducting fibers. In 
contrast, very low motor nerve conduction velocities (e.g. 20 mls) may be found in 
patients who are able to walk because little conduction block is present. This may 
be seen in patients suffering from HMNS type I (HMSN) or ClOP. 
It is not possible to compute m-NCVs in the distal part of the nerve. Not only is it 
difficult to measure distances accurately, also conduction is not a homogeneous 
process. The terminal motor twigs become thinner and therefore conduction veloci-
ty decreases. Finally, synaptic delay occurs at the motor endplate. Therefore, 
conduction in the final part of the nerve is simply given as the DML; it is often 
prolonged in demyelinating polyneuropathies. 
2.2.3.3 Excitability 
In routine nerve conduction studies, it is a prerequisite to stimulate the nerve supra-
maximally, i.e. twice the minimal stimulus strength needed to elicit a maximal 
CMAP amplitude (i.e twice the stimulus threshold). In normal nerves, this thres-
hold is reached by rather small electrical stimuli if conventional surface stimulation 
electrodes are applied (e.g. 0.3 msec. duration and 10 mA). By definition, CMAPs 
will not further increase in amplitude if stronger stimuli are applied. However, in 
some nerves the threshold is far beyond that of normal nerves. Therefore, in such 
cases, stimulus strength has to be augmented until the CMAP amplitude does not 
grow further. If not recognised, this phenomenon may give rise to major pitfalls in 
CMAP amplitude measurement (fig. 4B,4). Particularly, where nerves are deeply 
situated, which is usually the case for proximal stimulation sites, it may give rise to 
falsely low CMAP amplitudes mimicking conduction block. In our experience 
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excitability is often changed in CIDP and HMSN type I and sometimes in GBS in 
the post-acute phase. 
2.2.4 Motor nerve conduction studies in clinical practice; some guidelines 
In addition to motor nerve conduction studies other electromyodiagnostic tests like 
sensory nerve conduction studies and needle electromyography may be indicated. 
With these teclmiques the electrodiagnostic characteristics of several neuropathies 
can be evaluated. These are summarised in table I. 
In practice, one has to chose which nerves are to be tested. The clinical findings 
and the condition of the patient determine the choice of the number and kind of 
nerves to start with. The findings in the initial part of the investigation will further 
determine the strategy. 
For screening purposes, testing of one nerve in the upper- and lower extremity is 
minimally required. In the upper extremity the ulnar nerve is preferably tested. Due 
to its superficial position over an extensive length this nerve is easily accesible for 
tracing focal conduction block. This nerve can be stimulated stepwise by moving 
the electrode inch by inch over its entire length between wrist and axilla. This 
procedure is therefore called "inching". CMAPs are recorded from the hypothenar 
(abductor digiti quinti). An advantage is that this muscle is far apart from the 
thenar muscles, so that volume conducted thenar CMAPs, elicited by unintentio-
nally stimulated median nerve fibers, will have minor or no influence on hypo-
thenar CMAP. In the lower extremity the peroneal nerve is very suitable and in 
case of muscle fiber degeneration of the extensor digitorum brevis the posterior 
tibial nerve is a good alternative. CMAPs can then be recorded from muscles in the 
sole of the foot. 
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Table I. Electrodiagnostic characteristics of several neuropathies. 
Characteristically increased (I), decreased (I), unchanged (=); the sensitivity and 
specificty have not always been determined. If characteristic changes are possible, 
but not usually present this is indicated with the =/ sign. 
GBS: Guillain Barre syndrome; CIDP: Chronic Inflammatory Demyeliniting 
Polyneuropathy; HMSN I: Hereditary Motor Sensory Neuropathy (demyelinating 
type); MMN: Multifocal Motorneuropathy with persistent conduction block; DML: 
Distal motor latency; m-NCV: Motor nerve conduction velocity; reduction: reduc-
tion of CMAP amplitude after proximal compared to distal stimulation; duration: 
duration of negative part of CMAP; =: unchanged; ': all characteristics tend to be 
focal. 
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Table I. Characteristic changes in electrodiagnostic parameters in several neuromuscular disorders. 
DML m-NCV distal reduction duration of excitability sensory ref. 
CMAP of CMAP amplitude 
amplitude CMAP 
amplitude 
GBS ~/1 ~/+ ~/T ~/1 ~/1 
CIDP 11 ~/+ ii 
HMSNI 11 ~ ~ iii 
Axonal pnp ~ ~Il ~ ~ iv 
Motor neuron ~ ~/1 ~ ~ ~ ~ v 
disease (ALS) 
MMN ~ *1 ~ ~ vi 
Critical ~ ~ ~ ~ vii 
illness pnp 
(Lambert, 1960; Brown, 1984a; Albers, 1985; van der Meche, 1988a) 
II (Lewis, 1982b; van der Meche, 1989; Dijck, 1993b). 
iii (Lewis, 1982b; Dijck, 1993a) 
iv (Donofrio, 1990) 
v (Bradley, 1987) 
vi (Lewis, 1982a; Krarup, 1990; Pestronk, 1988; Parry, 1993) 
vii (Bolton, 1986; Zodochne, 1987) 
If no abnormalities are found in routine electrodiagnostic testing, the number of 
nerves has to be extended and proximal parts may be included by the study of late 
responses. Late responses such as F -responses are only relevant for the study of 
nerve conduction velocities. Their absence is no proof for proximal conduction 
block since they are not always present in healthy subjects and evoked F-responses 
may be blocked in distal segments if the distal CMAP is reduced due to distal 
demyelination or dying back axonal neuropathy. Conduction block, confined to 
very proximal sites is difficult to detect. Although it is conceivable to stimulate the 
ventral roots, supramaximal stimulation was proved in our lab to be unreliable both 
for magnetical as electrical stimulation. 
In conclusion: careful CMAP measurement is a necessity for adequate electrodia-
gnostic testing in addition to conventional conduction velocities. It is the only 
reliable way to detect conduction block and temporal dispersion, both important 
electro diagnostic signs of demyelination. Using the guidelines presented it is easy 
to avoid the majority of technical pitfalls. 
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Chapter three 
Electrodiagnostic tests in the Guillain-Barre syndrome, 
a review of the literature since 1960 
3.1 Historical perspectives 
In his original report, dating from 1960, Lambert (Lambert, 1960) described a 
Guillain-Barre patient, whom he tested electrodiagnostically 14, 27 and 81 days 
after onset of the disease. On distal stimulation of the median, ulnar and peroneal 
nerve he found a normal CMAP. With more proximal stimulation, however, he 
found evidently lower amplitudes (CMAP-reduction). He ascribed this phenome-
non to conduction block. Therefore this author may be regarded as the first one to 
formulate the concept of length dependent CMAP amplitude reduction, which has 
since proven to be the most typical electrodiagnostic sign in demyelinating 
polyneuropathy. In addition he found only slightly reduced conduction velocities in 
early stages of the disease (fig. 5). 
Many electrodiagnostic studies in GBS have been performed since. However, the 
fact that CMAP amplitude reduction, reflecting conduction block, as a cardinal 
sign in GBS, was not appreciated generally until the early 80s. One exception, 
however, can be found in a study by McQuillen (McQuillen, 1971). Surprisingly 
enough, these authors did not comment on the importance of this finding. 
In 1964 McDonald performed electrophysiological and morphological studies in 
artificially induced demyelination on an animal model (McDonald, 1963a, 1963b; 
McDonald et aI., 1982). It was not until similar studies had been performed in the 
early eighties (Antigalactocerebrosidase serum model:(Lafontaine et aI., 1982) 
EAN model:(Saida et aI., 1979; Sumner et aI., 1982; Hahn et aI., 1985; ), AIDP 
serum model: (Feasby et aI., 1982; Harrisson et aI., 1984), that repolis started to 
appear on the nature and pathophysiological backgrounds of electrodiagnostic fin-
dings in peripheral nerves in the human (Sumner, 1981; Brown et aI., 1981, 1984; 
Feasby et aI., 1985). These reports led to re-appreciation of the CMAP and stressed 
the importance of measuring CMAP amplitudes for the assessment of conduction 
block in patients with demyelinating polyneuropathy. 
3.2 Nerve Conduction Studies 
The occurrence of nOl'lIIol nerve conduction velocities in GBS patients has been 
reported frequently (Lambeli 1964: in 14%; Humphrey 1964; Bergamini 1966; 
McQuillen 1971: in 41%; Eisen 1974: in 5%; Mcleod 1976: in 14%; Raman,1976: 
in 13%; McLeod 1981: in 9%; Niewiadomska 1981: in 57%; Brown,1981,1984 in 
the majority of their patients; Walsh,1984; Albers 1985; Ropper 1990). McLeod 
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(1981) stressed the fact that in one patient nerves with normal and abnormal 
conduction can be found simultaneously (McLeod, 1981). 
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Fig. IX.7. GlIillain·Barre syndrome. Action potentials of the abductor pollicis muscle 
e\'oked h)' maximal stimulation of the median Ilene in the upper arm, at the elbow 
and at the wrist. R. is the recording site. Tests were made 14, 27, and 81 da}'s after 
acute onset of the disease. At 14 dal's, although the patient was quadriplegic, stimula-
tion of the nerve at the wrist c\'okcd an essentially normal response front the muscle, 
indicating that wallerian degeneration had not DeClined. There was little or no evj· 
dence of fibrillation on needle electrode examination of the muscle. Strength-duration 
curves were normal. Stimulation of the nCl"\'C at the elbow and upper arm evoked only 
a small response from the abductor pollicis muscle indicating failure of excitability 
and/or conduction of the majority of motor fibers to this muscle in the more proximal 
part of their course. With time, conduction returned in the proximal part of the nen'e. 
The distal part of the nerve remain cd excitable. Recover)' of the response to stimula· 
tion at the elbow began earlier and occurred more rapid I)' than recovcr)' of the strength 
of voluntary contra('(iun. A similar sequence of eVellts occurred in the ulnar and pero· 
neal nen'('s. 
Fig. 5. Lambert's Guillain·Barre patient (Lambert, 1960). 
Conduction slowing was found by Lambert (1964) in 61 % of his patients (NCV 
below 70% of the normal mean). Most pronounced slowing was found at usual 
compression sites and in 25% a prolonged DML was detected (Lambeli and Mul-
der, 1964). McLeod (1976,1981) found conduction slowing in 49% of their pa-
tients (upperlimb nerves below 40 m/s and in peroneal nerve below 40m/s) (McLe-
od et aI., 1976, McLeod 1981). Brown (1964) repOlied abnormal DML in 30% and 
slowed m-NCV in 13% in 46 patients, which were tested within 2 weeks after 
onset of motor symptoms (Brown et aI., 1984). Cornblath tested 210 patients 
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electrodiagnostically (50% were tested within 10 days and more then 75% within 
15 days after onset); 24% had abnormal m-NCV and 40% had abnormal DML 
(Comblath et aI., 1988). In a prospective study, 25% of the patients had slowing in 
an early stage in at least two nerves (Ropper et aI., 1991). 
In a serially tested group of GBS patients, particularly prolongued DML and lower 
CMAP and in lesser extent slowed m-NCVs were found within one week of onset 
(Rudnicky et aI., 1992) . 
In addition, several authors found prolongued DML in the presence of normal or 
near normal conduction velocity in more proximal segments (Bannister and Sears, 
1962; Isch et aI., 1964; Bergamini et aI., 1966; McQuillen, 1971; Eisen et aI., 
1974; Kimura, 1975; Kimura and Bosch, 1975; McLeod et aI., 1976; McLeod, 
1981). 
Comparison of sensOIJ' versus molar nerve conduction velocities. 
Eisen (1974) found that compound sensory nerve action potentials (CSNAP's) 
were absent in ulnar and/or median nerve in 58%, and McLeod found sensory 
nerve conduction abnormalities in 76% of their patients (Eisen et aI., 1974; McLe-
od, 1981). Ropper found normal sensory conduction in two or more nerves in 37% 
of 107 patients (Ropper et aI., 1985). Predilection for motor over sensory abnonna-
lities were also described (Eisen et aI., 1974; McLeod, 1981). In a retrospective 
study Albers (1986) found a consistent predominance of motor over sensory 
abnormalities at all stages of the disease (e.g. in 88% and 25% of the patients, 
respectively, in the first week). Particularly sural nerve conduction was normal in 
contrast to motor nerve conduction (Albers et aI., 1985). Others, including our own 
group, found normal sensory potentials despite severe motor abnormalities within 
the same compound nerve in several patients (Raman and Taori, 1976; van der 
Meche et aI., 1988a). 
In serial nerve conduction studies initially normal or near normal conduction velo-
cities were found (Peterman et aI., 1959; Lambert, 1960; Humphrey, 1964; Kaeser, 
1964; Lambert and Mulder, 1964; McQuillen and Gorin, 1969; Bigot and Goulon, 
1970; Eisen et aI., 1974; Kimura, 1975; McLeod et aI., 1976; Raman and Taori, 
1976; Hausmanova et aI., 1979; Wexler, 1980, 1988; McLeod, 1981). Generally 
the observed changes were reported to occur seemingly at random; there was no 
correlation with clinical deficit in most studies. Albers pooled the electrodiagnostic 
findings, combining observations on 180 patients, who were tested in the second 
until the 20th week after onset of the disease. Motor conduction velocities peaked 
at 3 weeks after disease onset and sensory abnormalities 1 week later. In comple-
tely recovered patients, normal m-NCVs were found in only 1 of 10 patients after 2 
years (Martinez et aI., 1977). In contrast McLeod found normal NCVs in most of 
his patients 6 months to 5 112 year after onset (McLeod, 1981). 
F-response latencies have been used to detect conduction abnormalities in proxi-
mal nerve segments (roots, plexus). In patients with normal m-NCVs the incidence 
of abnormal F-responses varies considerably: by Kimura (1975 et aI., 1978) in 
23%, by Lachman (1980) in 18%, by Walsh (1984) in 12%, by Mills (1985) in 
24%, by Ropper (1985) in 68%. In his series an abnormal F-response was the 
exclusive finding in 27%. Albers found in his patients the highest incidence of 
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abnormal F-responses in the 3rd to 5th week after onset (Kimura et aI., 1975; King 
and Ashby, 1976; Kimura, 1978; Lachman et ai., 1980; Walsh et aI., 1984; Albers 
et aI., 1985; Mills and Murray, 1985; Ropper et aI., 1985). Cornblath (1988) found 
46% abnormal F-responses in 210 GBS patients, however m-NCV were not al-
ways normal in this group (Cornblath et ai., 1988). 
Proximal conduction block: using electrical percutanous stimulation of the cervical 
roots, conduction block in proximal nerve segments was found by Brown 
(1984,1988) in 7 of 17 patients and by Mills (1985,1986) in 5 out of 17 patients 
(Brown et aI., 1984; Brown, 1988; Mills and Murray, 1985, 1986; van del' Meche 
et al. 1986). One study, using this technique, showed recovery of proximal 
conduction block during clinical recovery of motor symptoms in 3 GBS patients 
(Berger et aI., 1988). However, these studies should, however, be interpreted with 
care, as supramaximal stimulation of deeply seated nerve bundles may be difficult, 
especially in pathological changed fibers (chapter 2.2). 
Temporal dispersion and conduction block was first described by Lambert in a 
serial study in a GBS patient (Lambert, 1960). He used surface disk electrodes to 
record motor responses. In addition, the implication of increased CMAP duration 
for detection of abnormal temporal dispersion was stressed by this author. Several 
authors observed dispersion or complete absence of the evoked CMAP on distal 
nerve stimulation, albeit by means of the teclillically less reliable use of needle 
electrodes (Cerra and Johnson, 1961; Bannister and Sears, 1962; Banerji, 1972; Ei-
sen, 1974). Conduction block was clearly revealed but not commented on in a 
pUblication by McQuillen in 1971 (MCQuillen, 1971). Since, the incidence of 
conduction block, as defined by CMAP amplitude reduction over the length of the 
forearm, has varied from 20% to 60% (Lewis and Sumner, 1982; Brown et aI., 
1984; Feasby et ai., 1985; Olney et aI., 1987; Albers and Kelly, 1989; Barohn et 
aI., 1989; Uncini et aI., 1991; Lange 1992). Brown et al. defined conduction block 
as a CMAP amplitude reduction of more then 20% over the length of the forearm, 
precluded that the CMAP duration does not increase by more than 15% (Brown et 
aI., 1984). In 68.4% of his patients conduction block was detected in at least one 
nerve within two weeks of disease onset. In 15 of 20 nerves a CMAP reduction of 
more than 50% was found in this study. Cornblath et al. tested 210 patients electro-
diagnostically (50% within 10 days and more than 75% within 15 days after onset 
of the disease) (Cornblath, 1990; Cornblath et aI., 1991). He found in 20% abnor-
mal distal CMAP amplitudes and in 30% abnormal CMAP reduction. In the retro-
spective study of Albers (1985), 50% of the patients had a low CMAP amplitude 
on distal stimulation in the first week of the illness, which typically further decrea-
sed in the second through the third week (Albers et aI., 1985). A model of random 
conduction block in GBS was proposed by van del' Meche and Meulstee (van del' 
Meche and Meulstee, 1988). 
Today, no generally accepted electrodiagnostic criteria for conduction block are 
esthasblished. 
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3.3 Correlation with clinical disability 
Isch (1962) found clinical recovery preceeded m-NCV normalisation, while Berga-
mini (1966) found a correlation between rate of clinical deterioration and conducti-
on slowing (Isch et aI., 1962; Bergamini et aI., 1966). Others could not detect a 
correlation of conduction abnormalities with clinical disability (McQuillen, 1971; 
McLeod et aI., 1976, 1981; Hausmanova et aI., 1979; Wexler, 1980). Even normal 
nerve conduction velocities in peripheral nerves have been found despite clinical 
disability (Lambert and Mulder, 1964; Bergamini, 1966; Eisen et aI., 1974; Raman 
and Taori, 1976; McLeod et aI., 1976, 1981). Several authors have found conduc-
tion slowing to be correlated to prolonged time to recover in some of their patients 
(Eisen, 1974; Humphrey, 1964). In contrast McQuillen (1969) found conduction 
slowing to be associated with outcome (McQuillen and Gorin, 1969). However, in 
the group of 7 patients with fast recovery, 6 children, known to have a better a 
priori outcome, were included. Eisen (1974) and Wexler,(l980) found that sensory 
nerve conduction may further decrease ,in the presence of clinical improvement 
(Eisen et aI., 1974; Wexler, 1980). Eisen (1974) and Raman (1976) found that the 
presence of denervation potentials was associated with increased recovery time 
(Eisen et aI., 1974; Raman and Taori, 1976). Berger showed recovery of proximal 
conduction block at the time that motor deficit vanished in 3 GBS patients using 
cervical root stimulation (Berger et aI., 1988). We found a correlation between 
CMAP amplitude after distal stimulation and clinical deficit (van del' Meche et aI., 
1989). 
3.4 Diagnosis 
Most authors have agreed that electrodiagnostic tests are important to support 
clinical diagnosis of demyelinative polyneuropathies (Eisen et aI., 1974; McLeod, 
1981; Kelly, 1983; Takeuchi et aI., 1984; Albers et aI., 1985; Albers and Kelly, 
1989; Cornblath, 1990; Olney et aI., 1990; van del' Meche et al. 1991; Bromberg, 
1992; Unchini, 1993). Several different sets of criteria have been proposed, all with 
resulting different sensitivity and specificity (Kelly, 1983; Albers et aI., 1985; 
Albers and Kelly, 1989; Cornblath, 1990; Bromberg, 1992). These sets, however, 
were mainly constructed for and tested in chronic demyelinating polyneuropathies, 
in which m-NCVs more frequently show severe slowing compared to GBS. There-
fore, their sensitivity for the diagnosis of GBS remains to be esthablished. 
3.5 Prognosis 
In mostly retrospective studies, low CMAP-amplitude after distal stimulation has 
been found to correlate with poor recovery (Ropper et aI., 1986; Gruener et aI., 
1987; Cornblath et aI., 1988; McKahn et aI., 1988; Miller et aI., 1988; Winer et aI., 
1988; Meulstee et aI., 1991; van del' Meche et aI., 1992). The presence of denerva-
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tion potentials predicted poor outcome in several studies (Brown et al. 1984; Feas-
by et aI., 1986; Gruener et aI., 1987; McLeod, 1981; Miller et aI., 1988). A similar 
but weaker predictive power was esthablished for m-NCV (Cornblath et aI., 1988). 
Several authors found that patients with denervation potentials had slower recovery 
(Eisen et aI., 1974; Raman and Taori, 1976; Mcleod, 1981). Others described the 
association between low CMAP amplitudes with denervation potentials and poor 
prognosis (Miller et aI., 1988; Cornblath et aI., 1988). 
3.6 Subtypes 
Ropper described three predilection sites of conduction deficit: distal, intermediate 
and proximal (Ropper et aI., 1990, 1991). Brown reported distal and proximal 
conduction failure in addition to conduction failure at usual compression sites to 
predominate (Brown et aI., 1991). Most authors hypothesise that failure of blood 
nerve barrier plays an important role in the distribution of conduction deficit. 
In 1988 we suggested that two patterns of conduction block might be distinguis-
hed. In one pattern the sensory system was spared and motor conduction block 
occurred more or less randomly over the length of the nerve. In the other pattern 
sensory potentials disappeared and motor conduction block was suggested to be 
more located in the distal parts of the nerves (van der Meche et aI., 1988a, 1988b). 
In chapter 4 it will be discussed that these patterns in fact appear to be extremes of 
a continuum. 
3.7 Axonal degeneration 
Several authors found denervation potentials in GBS with incidences varying from 
23%-100% (Eisen et aI., 1974 in 23%; Dejesus et aI., 1974 in 54%; Raman and 
Taori, 1976 in 20%; Niewiadomska and Wochnik-Dyjas, 1981 in 30-70%; Brown 
1981 in all of 10 patients; Albers 1985, 1986; van der Meche et aI., 1988a, 1988b). 
Denervation potentials were most often found in distal muscles (Raman and Taori, 
1976; Niewiadomska and Wochnik-Dyjas, 1981; Brown et aI., 1984) and predomi-
nantly in lower limb muscles (Brown et aI., 1984). In the serial retrospective study 
of Albers, denervation potentials were most abundant in the 3rd to the 5th week 
(Albers et aI., 1985). Dejesus and Martinez (1977) performed the first quantitative 
myography and found signs of axonal reinnervation well into the recovery phase 
(Dejesus, 1974; Martinez et aI., 1977). 
Mostly, axonal degeneration has been ascribed to be due to demyelination ("by-
stander phenomenon") (King and Ashby, 1976; Madrid and Wisniewsky, 1976; 
Asbury and Johnson, 1978; Said et aI., 1981; de Waal, 1990), although several 
authors raised the possibility of a primary axonal lesion (Niewiadomska and 
Wochnik-Dyjas, 1981; Albers et aI., 1985). Feasby was the first author, characteri-
sing an acute axonal subtype of GBS defined by widespread axonal degeneration 
and inexcitable motor nerves along with poor recovery (Feasby et aI., 1985, 1993). 
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Since then, some have argued that the distinction of an axonal subtype was not 
warranted, because they found signs of demyelination prior to development of 
severe axonal involvement (van del' Meche, 1991a; Triggs et aI., 1992; Brown, 
1993). 
3.8 Summary and conclusion 
Since Lambert's original report in 1960 the following basic features have been 
distillated from electrodiagnostic studies in GBS: early conduction block as reflec-
ted by low distal CMAP amplitudes and CMAP reduction with more proximal 
stimulation and in a later phase of the disease conduction slowing (Cornblath, 
1990). Often, however, different electrodiagnostic studies in GBS show conflicting 
results. This may be due to the variability of the lesions intrinsic to the disease, but 
likely they are also caused by the very variable timing of the observations in relati-
on to the phase of the disease; many of the earlier studies were done in the plateau 
or recovery phase and not in the early phase (Kaeser and Lambelt, 1962; Pleasure 
et aI., 1968; McQuillen and Gorin, 1969; Eisen, 1974; Martinez et aI., 1977; 
Hausmanova et aI., 1979). In several studies, factors associated with poor progno-
sis were identified. Especially low CMAP amplitudes and denetvation potentials 
were significant predictors of poor outcome; decreased m-NCV was a less reliable 
predictor of poor outcome. 
Generally these studies have shown what electrodiagnostic parameters are to be 
tested in Guillain-Barnl syndrome. Over the recent years CMAP parameters have 
been more important than the study of nerve conduction velocities. 
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Chapter four 
Electrodiagnostic findings and patterns In the Guillain-
Barre syndrome 
4.1 Introduction 
In the GuiIlain-Barre syndrome electrodiagnostic evidence for demyelination is 
regarded as strong diagnostic support (Asbury and Cornblath, 1990). Slowing of 
conduction has at first been emphasised, but this may appear relatively late in the 
disease (McLeod, 1981). Later, conduction block and abnormal dispersion of the 
CMAP between proximal and distal stimulation sites have been discussed (Brown 
and Feasby, 1984; van del' Meche et aI., 1988b; Albers and Kelly, 1989; Cornblath, 
1990; Feasby, 1992). Low CMAPs after distal stimulation have been shown to 
have prognostic value, but is not specific for demyelination (Winer, 1985; Corn-
blath et aI., 1988; Albers and Kelly, 1989; Meulstee et aI., 1991; van del' Meche et 
aI., 1992). In general a substantial variability between patients and between studies 
has been found. This may in part be due to the timing of the electrodiagnostic 
studies relative to the phase of the disease. Many studies have been transversal, 
retrospective or without a standard time schedule. At the other hand, different 
pathophysiological mechanisms may exist in GBS leading to different electrodiag-
nostic patterns. We have described such patterns in individual GBS patients, that 
were either characterised by a pure motor form with random conduction block or 
by a sensory motor form with predominantly low distal CMAPs and prolonged 
distal motor latencies (van del' Meche et aI., 1988a, 1988b). 
In the Dutch GBS trial we were able to study longitudinally 135 patients following 
a fixed time schedule. Three electrodiagnostic studies were longitudinaly perfor-
med at entry and one and four weeks later to answer the following questions: I. 
How do the abnormalities described above develop during the course of the disea-
se?; 2. What is the optimal timing for electrodiagnostic studies in GBS patients 
with regard to an optimal yield of abnormalities to use for diagnostic and progno-
stic purposes?; 3. Is it possible to characterize subgroups of patients with defined 
electrodiagnostic patterns? 
4.2 Patients and methods 
147 Patients fulfilling the criteria for acute Guillain-Barre syndrome, were follo-
wed for 6 months in the multicentre Dutch Guillain-Barre Trial, which was a 
randomised trial comparing intravenous immune globulin and plasma exchange 
treatment (van del' Meche et aI., 1992). Patients had to be ill for less than two 
weeks and had to be unable to walk independently to be included in the study. 
Dependent on the clinical condition, electrodiagnostic testing (EMG) was perfor-
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med in warm EMG rooms or intensive care units. Normal reference values were 
obtained according to the same EMG protocol in a group of 45 healthy volunteers. 
Using linear regression, we constructed temperature dependent limits of normal for 
distal motor latencies and nerve conduction velocities. 
Ulnar and median motor and sensory nerves were tested, using standardised con-
ventional techniques. The peroneal motor nerve and sural nerve were additionally 
tested in part of the centers. As a group, these patients were not different from the 
patients in the centers where the peroneal and sural nerves had not been tested. 
Motor nerve conduction velocities, distal motor latencies and CMAPs were obtai-
ned after distal and proximal stimulation (Le. wrist and elbow, ankle and knee). 
Sensory nerve conduction velocities (s-NCY) and CSNAPs were obtained antidro-
mically using recording electrodes on the fifth and second fingers, respectively and 
for the sural nerve on the foot. Minimal F-response latencies were obtained after 
20 stimuli applied distally. F-M latencies were computed by subtracting the distal 
CMAP latency from the F-response latency. 
Utmost care was taken to stimulate nerves supramaximally and to search for the 
maximal CMAP above the muscle belly with surface disk electrodes. CMAP-
amplitudes of the hypothenar, thenar and extensor digitorum brevis muscles were 
measured as peak-to-peak values as well as duration of the negative phase. CMAP-
amplitude reduction is important to diagnose demyelination. In general, a reduction 
of the CMAP after proximal versus distal stimulation with a higher percentage than 
in a reference group has been taken as abnormal. 20% Reduction is taken as a limit 
by several authors (Feasby et aI., 1985). Because the error of CMAP measurement 
is approximately I mY, the use of a percentage as the criterion for abnormal ampli-
tude reduction is only reasonable if the CMAP amplitude after distal stimulation 
(distal CMAP) is not too low. Below 5 mY the error of I mY in itself may lead to a 
CMAP reduction percentage of 20. Therefore, we have taken as evidence for 
significant amplitude reduction a decrease of the CMAP amplitude beyond the 
limit of normal for a particular nerve; in the case ofa low CMAP «5 mY) we take 
a decrease of I mY. 
To obtain an impression of temporal dispersion, the percentage of increment of the 
duration of the negative phase of the CMAP was computed. 
Myography was performed using concentric needle electrodes in the abductor 
polllicis brevis, abductor digiti minimi and anterior tibial muscles. At several sites 
in the muscle, the presence and density of denervation potentials were estimated as 
follow: 0 = not present; I = a few present; 2 = many denervation potentials, but 
baseline not completely filled; 3 = many denervation potentials and baseline com-
pletely filled. Recruitment pattern on maximal voluntary effort (pattern) was also 
tested and estimated as follow: interference pattern (lP) = normal i.e. full pattern; 
mixed pattern (MP) = moderately decreased pattern; single pattern (SP) = severly 
decreased pattern; 0 = no motor unit potentials recognisable. Skin temperature of 
all stimulation and recording sites as well as muscles were measured. 
Electrodiagnostic testing was scheduled within two days after entry, one week later 
and one month later. 
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Of all electrodiagnostic variables, median values and their 5 - 95 interpercentile 
range were computed as well as the average surface skin temperature. 
In addition, the percentage of patients with abnormal values according to tempera-
ture dependent normal values were computed for variables in each of the three 
EMGs. Similarly, the percentage of abnormal F-M wave latencies was counted; 
however, this was only done in nerves with a normal distal m-NCV. 
The change of values throughout the three EMGs was computed, only if the diffe-
rence in skin temperature between consecutive examinations did not exceed 1" 
Celsius. Formal cluster analysis, using the computer programm SSPS, was perfor-
med to search for subgroups. 
4.3 Results 
Tillling of EMG was scheduled according to the time of entry into the trial. At that 
moment patients were unable to walk independently. At the time of the first EMG, 
they had been complaining of weakness for an average of 6 days (90% of the 
patients: 2-15 days) (table 2). Average skin temperature varied from 30.4" - 32.4" 
Celsius for most nerves (table 3). 
Table 2. Duration of weakness (days) at the moment ofEMG. 
median range 5% - 95% 
EMGI 6 days 2 - 15 days 
EMGII 13 days 9 - 22 days 
EMG 1II 34 days 29 - 49 days 
Distal illataI' latencies and conduction velocities: The means and ranges for all 
three EMGs are given in table 3. It appears that the average DML and NCV for the 
group do not change much during the course of the disease. In table 4 the percenta-
ges of patients are given, who had an abnormal value. In the first EMG about 80% 
of the patients had an abnormal DML in the upper limb nerves. About 50% had 
abnormal m-NCVs and s-NCVs in the first EMG. The sural nerve was involved in 
about 40%. All these percentages increased somewhat over the period of a month. 
The percentage of patients with abnormal F-M wave latencies in combination with 
normal m-NCVs was 8% - 13% in upper limb nerves and 0% in the peroneal 
nerve. F-responses could not be elicited in 9%, 5% and 23% from median, ulnar 
and peroneal nerve respectively in the first EMG. 
CA1AP amplitudes after distal stimulation: Median values were far below lower 
limit of normal (LLN) in all three EMGs (fig. 6). The percentage of patients with 
abnormal CMAP amplitudes in the first EMG was 86% and 97% in the upperlimb 
nerves (table 4) and 75% in the peroneal nerve. The incidence of inexcitable nerves 
became maximal in the third EMG. It was more frequently observed in the perone-
al nerve (17%) compared to upper limb nerves (both 6%) (table 3). 
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Table 3a. Median and range of conduction velocities in EMG I. 
mean range temp SD n 
DML 
ulnar 3.8 msec. 2.6-6.4 31.6·C 2.2 123 
median 5.1 msec. 3.2-11.2 31.9·C 1.9 119 
peroneal 5.5 msec. 3.7-9.4 30.4·C 2.1 52 
m-NCV 
ulnar 52 m/sec. 34-64 32.2·C 1.7 ll9 
median 47 m/sec. 26-60 32YC 1.5 ll7 
peroneal 39 m/sec. 21-53 30.8·C 1.4 51 
s-NCV dis!. 
ulnar 44 m/sec. 33-60 31.0·C 4.2 73 
median 50 m/sec. 30-62 31.6·C 2.3 77 
sural 43 m/sec. 33-54 30.4·C 1.9 32 
s-NCV pl'Ox. 
ulnar 58 m/sec. 45-73 31.8·C 1.8 62 
median 57 m/sec. 40-68 32.2·C 1.7 63 
Tabel 3b. Median and range of conduction velocities in EMG II. 
mean range temp SD n 
DML 
ulnar 3.9 msec. 2.4-9.5 32.0·C 1.9 118 
median 5.7 msec. 3.0-14.2 32.I·C 1.8 ll8 
peroneal 5.4 msec. 3.7-13.3 30.rC 2.2 45 
m-NCV 
ulnar 50 m/sec. 27-63 32.2·C 1.6 116 
median 47 m/sec. 25-58 32.4·C 1.6 115 
peroneal 37 m/sec. 18-55 31.1"C 1.8 44 
s-NCY dis!. 
ulnar 44 m/sec. 22-61 31YC 3.0 66 
median 50 m/sec. 36-62 31.8·C 3.0 66 
sural 42 m/sec. 33-52 30.5·C 2.3 24 
s-NCV prox. 
ulnar 58 m/sec. 39-71 32.0·C 2.0 56 
median 57 m/sec. 29-69 31.00C 1.7 56 
46 
Table 3c. Median and range of conduction velocities in EMG III. 
mean range temp SD n 
DML 
ulnar 4.2 msec. 2.5-11.3 31.l"C 2.2 108 
median 6.2 msec. 3.3-16.9 31.4·C 2.0 107 
peroneal 7.0 msec. 3.2-15.6 29.5·C 2.1 36 
m-NCV 
ulnar 46 m/sec. 19-62 31.7"C 1.9 103 
median 45 m/sec. 21-57 32.1 ·C 1.7 104 
peroneal 37 tn/sec. 24-48 30.4·C 1.6 34 
s-NCV dis!. 
ulnar 41 m/sec. 18-56 30.5·C 2.5 71 
median 44 m/sec. 23-57 31.0·C 2.5 68 
sural 40 ntlsec. 14-59 29.4·C 2.2 18 
s-NCV prox. 
ulnar 56 m/sec. 42-69 31.0·C 2.0 55 
median 56 m/sec. 39-71 32.0·C 1.8 55 
CMAP-amplitude reduction with more proximal stimulation compared to distal 
stimulation: abnormal CMAP-amplitude reduction, defined as more than the upper 
limit of normal (ULN) but at least 1 m V were found in 32% in ulnar nerve, in 39% 
in median nerve and in 17% in the peroneal in the first EMG. The incidence of 
abnormal reduction tended to decrease in later EMGs (table 4). 
Dispersion oj CMAPs: median values obtained after distal stimulation exceeded 
the upper limit of normal in all nerves in the second and third EMGs (fig. 6). The 
CMAP was prolonged in about 50% in the first EMG in all 3 nerves and increased 
further by about 5 - 15 % in subsequent EMGs. The percentage with an abnormal 
increment in CMAP-duration with more proximal stimulation, varied from 17% -
39% in all three EMGs in all nerves (table 4). To estimate the diagnostic value of 
dispersion in addition to the DML and m-NCV we determined the incidence of 
abnormal dispersion in combination with normal DML or m-NCV. These inciden-
ces varied from 15% to 53% and from 0% to 26% respectively (table 5). 
CSNAP-amplitudes: Median values of CSNAPs obtained after distal stimulation 
were below LLN in the ulnar and median nerves in all three EMGs (fig. 6). In the 
first EMG, the percentage of patients with abnormal values was higher in the upper 
limb sensory nerves (22%) compared to the sural nerve (10%). This percentage 
increased by a futiher 10% during subsequent EMGs in all nerves tested. In additi-
on, the percentage of patients with amplitudes of 0 uV in upper limb sensory 
nerves in any EMG after distal stimulation varied from 31 % to about 39%, where-
as in the sural nerve it was 18% to 22% (table 4). 
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Table 4. Percentage of patients with abnormal findings in EMG I, II and III. 
limit EMGI 
" 
EMGII 
" 
EMG III 
" 
DML"i 
ulnar 83% 123 86% 119 85% 108 
median 79% 121 76% 118 77% 107 
peroneal 23% 53 38% 47 54% J7 
m-NCV§ 
ulnar 45% 119 56% 116 67% 103 
median 64% 117 65% III 67% 104 
peroneal 47% 51 48% 44 53% 34 
s-NCV dist§ 
ulnar 45% 73 52% 66 56% 71 
median 39% 77 38% 66 46% 68 
sural 28% 32 29% 24 r39% 18 
s-NCV prox§ 
ulnar 44% 62 43% 56 58% 55 
median 48% 63 48% 56 51% 55 
F·Mlal.' 
ulnar 30.0 rnsec. 13% (9%J 64 15% (4%) 68 16% [4%] 73 
median 28.6 InSCC. 8% 5%) 79 4% [6%J 79 12% [4%} 76 
peroneal 55.7 msee. 0% (23%) 22 25% [19%J 16 8% (25%J 12 
CMAP·amp distl 
ulnar IS.SmY. 97% {I%] i25 91% {6%} 126 88% {6%] 113 
median 12.3 mY. 86% (4'l10) i25 86% (6%] 127 81% [6%] 117 
peroneal 6.0mV. 74% [9%) 
" 
71% [13%] 55 75%[17%] 47 
CMAP·reduclion 
ulnar 32% 12. 36% 118 33% .., 
median 39% 119 29% 119 29% 109 
peroneal 17% 52 27% 44 3% 38 
CMAP·dur dist' 
ulnar 8.1 msec. 48% 93 65% 92 53% 81 
median 7.2 msec. 49% 87 74% 91 66% 83 
peroneal 6.7 msec. 55% 38 60% 3. 69% 26 
CMAP-dur incr.' 
ulnar 12% 21% 89 28% 89 39% 76 
median 12% 17% 82 34% 9. 30% 8. 
peroneal 19% 38% 37 25% 28 18% 22 
CSNAP-amp distl 
ulnar lOuV. 23%(31%] 121 24% {37%] 117 32%(30%] 109 
median lOuV. 22%[33%) 125 25% {39%] 121 29% {34%] 112 
sural 5uV. 10% {18%J 39 5% {17%J 3. 22%122%] 23 
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Values in square brackets represent the incidence of unelicitable responses not included in 
the percentage of abnormal values. Sensory nerve conduction velocities were obtained in 
the hand (s-NCV dist.) and in forearm (s-NCV prox.) segments. CMAP-amp dist. and 
CMAP-dur dist. indicates the CMAP amplitude and CMAP duration respectively, after 
distal stimulation. CMAP dur incr. indicates increment of CMAP duration between two 
stimulation points. ~ Upper limit of normal and § lower limit of normal according to our 
laboratory's reference values; in the case of DML and NCV according to temperature 
dependent limits. 
Density of denervation potentials: About 10% of the patients had denervation 
potentials in the first EMG, usually grade I or 2. The incidence and severity re-
ached a maximum in the third EMG (40%-65%) of all patients. Denervation poten-
tials were more frequently present in the anterior tibial muscle (65%) than in the 
small hand muscles ( 40%-43%) (table 6). 
Recruitment pattei'll on maximal voluntmy contraction: 41 %-62% of the patients 
had no voluntary recruitment pattern (0) or a severely decreased pattern (SP) at the 
first EMG. These percentages decreased between the second and the third EMGs 
(table 7). 
F-Iat. 0 150 msee. 
uln 
moo 
per 
CMAP-ampl. 0 3OmV. 
uln 
moo 
per 
CMAP-dur. 0 20 msec. 
uln ! I 
moo : I 
per I 
CSNAP-ampl. 0 
uln 
mOO 
sur 
Fig. 6. Median values, 5-th and 95-th percentile ranges of electrodiagnostic findings. 
Data obtained in the first, second and third EMG are represented by a bundle of three 
consecutive bars. Limit values are indicated by one vertical bar per bundle. 
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Table 5. Incidence ofabnonnal temporal dispersion ifDML or m-NCV are normal. 
EMGI EMGII EMG'", 
Abnormal dispersion with distal stimulation 
ulnar 29% (21) 29% (17) 19% (16) 
median 15% (26) 32% (28) 25% (25) 
peroneal 34% (41) 41% (29) 53% (17) 
Abnormal differential dispersion 
ulnar 17% (65) 18% (51) 26% (34) 
median 12% (42) 38% (40) 24% (34) . 
peroneal 26% (27) 4% (23) 0% (16) 
Incidence of abnormally long duration of CMAPs with distal stimulation in patients with 
normal DML (upper part) or abnormally large increase in duration of CMAPs with proxi-
mal compared to distal stimulation in patients with normal m-NCV (lower part). The 
number of patients with normal DML or normal m-NCV are given in parentheses. 
Table 6. Percentage of patients with denervation potentials in various muscles. 
EMGI EMGII EMG '" 
n n n 
M.ADV 9% 102 18% 107 40% 98 
M.APB 10% 106 18% 109 43% 98 
M.TA 9% 54 30% 56 65% 55 
Elec/I'odiagnoslic subtypes were not easily recognised. In an earlier study, some 
patients showed more or less random conduction block and sparing of the sensory 
fibers, while other patients showed low distal CMAPs, prolongued DMLs and 
disappearing sensory potentials (van del' Meche et aI., 1992). 
In the present study 27 patients (18%) had a pure motor form ofGBS both clinical-
ly and electrodiagnostically, but conduction block was variably present. Likewise 
in patients with mixed sensory motor involvement clear conduction block was 
sometimes present. In order to analyse whether two subgroups exist that merge into 
each other, or whether the variability of findings is better explained by a conti-
nmlln, cluster analysis has been performed, including all electrodiagnostic varia-
bles. This analysis refuted the hypothesis of two merging subgroups. 
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Table 7. Percentage of patients with reduced recruitment pattern (absent or single 
motor unit activity). 
EMGI EMGII EMG III 
n n 
n 
M.ADV 50% 103 42% 106 30% 98 
M.APB 41% 106 42% 107 32% 101 
M.TA 62% 55 53% 54 47% 53 
4.4 Discussion 
In the present study, in 90% of the patients, the first EMG was performed within 
two weeks after onset of the weakness. In all patients subsequent EMGs were 
made 1 and 4 weeks later. Therefore, the present study can be regarded as the first 
in which a large cohort of clinically defined GBS patients was tested longitudinally 
in an early stage of the disease. These patients were selected for the Dutch 
Guillain-Barre Trial and one of the entry criteria was inability to walk indepen-
dently more than 10 meters; therefore no conclusions may be drawn for mildly 
affected individuals. Due to the nature of the disease, patients were tested in clima-
te controlled EMG rooms or intensive care units in the 15 hospitals involved. We 
have paid particular attention to the problem of temperature control. The average 
skin temperature varied between 30.4" and 32.4" Celsius. We choosed not to warm 
patients up for practical reasons. Especially in the intensive care unit it is a cum-
bersome procedure. In addition it is conceivable that the gradient between skin 
temperature and nerve temperature varies considerably per patient as it depends on 
the soft tissue volume between skin and nerve. This is to say that two patients that 
have acquired the same skin temperature may still have significantly varying nerve 
temperatures. This method may lead to measuring errors, that are not possible to 
correct afterwards. Other approaches are to correct the measured values especially 
the DML and NCV for a deviation of the standard temperature or to apply limits of 
normal dependent on temperature. We applied both these methods; overall the 
differences were negligible, although for individual patients differences were 
observed. We have chosen to present the data with temperature dependent limits of 
the 45 normal controls to judge abnormalities in GBS patients. This is at present 
the most reasonable approach for this methodological problem, which is difficult to 
circumvent completely in clinical studies. 
DML and CMAP amplitudes after distal stimulation, were abnormal in more than 
80% in the first EMG. Therefore, early in the disease conduction abnormalities in 
distal segments of motor nerves predominate. In general slowed molo/' Gild sellSDlY 
NeV, were present in the first EMG in over 50%. In former studies a large variati-
on has been found in the percentage of patients with abnormal DML and NCVs 
(24% - 87%)(Lambert and Mulder, 1964; McQuillen, 1971; Eisen et aI., 1974; 
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Raman and Taori, 1976; Martinez-Figuerora et aI., 1977; McLeod, 1981; Takeuchi 
et aI., 1984; Walsh et aI., 1984; Albers et aI., 1985; Ropper et aI., 1985; Cornblath 
et aI., 1988; Winer et aI., 1988; Ropper, 1992). This may be due to sample size, 
timing ofEMG or selection of nerves. In accordance to others (Albers et aI., 1985; 
Ropper et aI., 1991), we found a slight preponderance for abnormalities of motor 
over sensory NCVs. We also confirmed a relative preservation of sural nerve 
conduction compared to upper limb sensory nerve conduction. This does not 
necessarily imply a different pathophysiological process. It may be that sensory 
nerves in the upper limbs, which in contrast to the sural nerve are mixed with 
motor fibers, are damaged by a bystander process in addition to the direct injury. 
Increased DML and decreased NCV reflect decreased conduction velocity in the 
fastest fibers in the distal segments of the nerve. Additional information concerning 
conduction velocity of slower conducting myelinated fibers may be obtained from 
dispersion of the CMAP. Differential dispersion, an increase of the duration after 
proximal versus distal stimulation, suggests slowing in part of the fibers between 
the stimulation points. This has been studied especially in those nerves where 
DML or NCV were normal. In individual nerves with normal DML and m-NCV, 
dispersion could still be found in 53%. This suggests that dispersion is an indepen-
dent and sensitive indicator of abnormal conduction. 
F -responses are commonly used for the assessment of conduction in proximal 
segments (Kimura et aI., 1975; Kimura, 1978; Lachman, 1980; Honavar et aI., 
1991). 
The incidence of abnormal or absent F-responses in the presence of normal m-
NCV in distal nerve segments varied from 0% to 25% in the three tested nerves, 
comparable to the 18-28% found in several earlier studies (Kimura et aI., 1975; 
Lachman et aI., 1980; Mills and Murray, 1985). In another study, however, the 
incidence was much higher (46%), but F-wave abnormalities were counted in the 
presence of abnormal m-NCV in the same nerve (Cornblath et aI., 1988). Because 
of the limited additional information by testing F-responses, F-response testing 
may be restricted to diagnostic investigation in patients with normal NCVs. 
Abnormally large CMAP-amplitude reduction between distal and proximal stimu-
lation sites, in the absence of an abnormal increase in duration of the CMAP, is a 
sign of conduction block in, and hence the hallmark of acquired demyelinating 
polyneuropathies. However, CMAP amplitude reduction can also be caused by 
temporal dispersion, due to increased phase cancellation. Since temporal dispersion 
is caused by slowing of conduction and therefore closely related to demyelination, 
we propose to use only CMAP amplitude reduction as one of the criteria for demy-
elinating polyneuropathies. Taking our criteria (see Methods) of CMAP decrease, 
the incidence of abnormal CMAP amplitude reduction at the first EMG was 31 %, 
37% and 15% for ulnar, median and peroneal nerve respectively. In previous 
studies, incidences of abnormal CMAP-amplitude reduction have been found to 
vary from 20%-60% (Lewis et aI., 1982; Brown and Feasby, 1984; Cornblath et 
aI., 1988; van der Meche et aI., 1988). 
Denervation potentials were most abundant in the third EMG. It was present in 
40% of small hand muscles in 60% of anterior tibial muscle. This is in agreement 
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with former studies in which the incidence of denervation potentials varied from 
20% to 64%. (Albers, 1985; Brown and Feasby, 1984; Eisen et aI., 1974; Raman 
and Taori, 1976). Since denervation potentials may be found already in the first 
EMG, it is suggested that at least in part of the patients loss of axonal function may 
start distally in the terminal motor nerve twigs and hence does not necessarilly 
forcast general axonal involvement. This would agree with reports that denervation 
is not necessarily related to poor outcome (Ropper et aI., 1990; Meulstee et aI., 
1991). 
The mean parameter values do not change substantially over the three EMG exa-
minations (Table 3). However, in the individual patients, more dramatic changes 
may be found in the progressive phase of the disease. We suggest that the optimal 
timing for final electrodiagnostic testing is at the nadir, which corresponds with the 
timing of our EMG II. This holds thrue both for diagnostic confirmation and to 
make a contribution in the evaluation of the prognosis. An earlier EMG may be 
falsely negative for the diagnosis and too optimistic for the prognosis. Later EMGs 
tend to diverge in a group with more severe changes in slowly improving patients 
and a group who is already improving. This is reflected by the increase of the 
measured range of many parameters in EMG III (table 2). 
In an earlier report we described two pallel'lls of conduction failure in GBS (van 
del' Meche and Meulstee, 1988), that later received support (Brown and Snow, 
1991). In one pattern, CMAP amplitudes became lower with progressively proxi-
mal stimulation of the nerve with preserved sensory conduction. In the other type 
low CMAP amplitudes on distal stimulation and proximal stimulation were accom-
panied by absent sensory conduction. In the present study, these two patterns were 
not found as two exclusive GBS subgroups. Cluster analysis showed that they most 
likely represent two extremes of a continuum. Nevertheless, the extremes that may 
exist in individual patients indicate that different immune mechanisms may playa 
role. A diversity of immunological and pathological mechanisms has been linked 
to the clinical and electrophysiological variability (van del' Meche et aI., 1994). 
From this study it is clear that the predominant electrophysiological changes are 
distal in the nerve and to a lesser extent in intermediate nerve segments. Part of the 
preponderance of a low distal CMAP, may perhaps be ascribed to the vulnaribility 
of the transition from myelinated to unmyelinated in the terminal nerve twig and 
loss of contact between the axon terminal and the muscle receptor due to axonal 
changes secondary to more proximal demyelination (Madrid and Wisniewsky, 
1976; de Waal, 1990). At the other hand it might be explained by the free access of 
soluble immune mediators to the intramuscular nerve branches, where the blood 
nerve barrier is absent. Activated T-cells, able to pass the blood nerve barrier, may 
be responsible for the more limited changes in the intermediate nerve segments 
(van del' Meche and van Doorn, 1994). 
Combined electro diagnostic and immunological studies are necessary to clarify 
this. 
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Chapter five 
Electrodiagnostic criteria for polyneuropathy and de-
myelination: application in 135 Guillain-Barre patients 
5.1 Introduction 
The Guillain-Barre syndrome is a subacute polyradiculoneuropathy causing severe 
flaccid quadriparesis. The precise aetiology is unknown but immune mechanisms 
are involved. In the recent past several therapeutic regimes have emerged, all of 
which help to reduce the duration and severity of the disease as well as the inciden-
ce and duration of respirator dependancy. (Guillain-Barre syndrome study group, 
1985; French cooperative group, 1992; van del' Meche et aI., 1992). Therefore, it is 
of major importance to have a firm diagnosis as early as possible. Clinical diagnos-
tic criteria have in general been shown to be reliable in the recently conducted 
clinical trials (Asbury and Cornblath, 1990; van del' Meche et aI., 1991). Electro-
diagnostic tests may, however, in some cases be necessary in the differential dia-
gnosis of GBS. Moreover, in cases of clinically defined GBS, electrodiagnostic 
studies and more specifically nerve conduction studies may show signs of demye-
lination, and thus further characterise clinically defined GBS as demyelinating 
GBS. This may, in the future, prove to be of help in the selection of specific treat-
ment modalities. In the present study we constructed two sets of electrodiagnostic 
criteria, which are based on the findings in patients included in the Dutch Guillain-
Barre Study (van del' Meche et aI., 1992). The first set can be used to prove the 
existence of a polyneuropathy. The second set was designed to test the presence of 
electrodiagnostic signs of demyelination. In addition, we tested several, previously 
published sets of electrodiagnostic criteria constructed for demyelinating polyneu-
ropathies (Albers and Kelly, 1989; Barohn et aI., 1989; Asbury and Cornblath, 
1990; Bromberg, 1991). 
5.2 Patients and methods 
Patients tested in this study were all included in the Dutch Guillain-Barre Trial 
which tested the efficacy of intravenous immune globulin versus plasma exchange 
in 147 patients (van del' Meche et aI., 1992). Patients had the disease for less than 
two weeks and were unable to walk independently. The results of electrodiagnostic 
tests were not part of the inclusion criteria. Electrodiagnostic tests were scheduled 
within two days of entry, one week later and one month later. 
The methods of electrodiagnostic testing have been discussed in detail elsewhere 
(van del' Meche et aI., 1988). In short: motor nerve conduction studies were perfor-
med in ulnar and median nerves. Shortest F-response latencies were measured after 
20 stimuli. Sensory nerve conduction velocities of ulnar and median nerves were 
55 
measured antidromically. Amplitudes and duration of the evoked motor and senso-
ry responses were measured using surface electrodes. Facultatively the peroneal 
and sural nerves were also tested. Using concentric needle electrodes, small hand 
muscles and anterior tibial muscles were tested for the presence of denervation 
potentials and to study recruitment pattern on maximal voluntary effort. 
Electrodiagnostic variables used for constructing the sets of criteria were: DML, 
m-NCV, F-response latency, CMAP amplitude and duration after distal stimula-
tion, ratio of distal versus proximal CMAP-amplitude, ratio of distal versus proxi-
mal CMAP-duration, CSNAP amplitude, s-NCV, recruitment pattern and presence 
of denervation potentials (table 8). Some values were not scored, but these were 
not particularly confined to a particular clinical state. In 135 patients at least one 
EMG was performed. 
Table 8. Proposed and tested set of electrodiagnostic criteria for polyneuropa-
thy. ULN upperlimit of normal; LLN lower limit of normal. 
At least 3 of the following abnormalities should be demonstrated per nerve in at least 2 
nerves: 
I. DML>ULN; 
2. m-NCV < LLN; 
3. F-wave latency> ULN ifm-NCV is normal; 
4. s-NCV < LLN; 
5. distal CMAP-amplitude < LLN; 
6. abnormal CMAP-amplitude reduction: 
CMAP-amplitude reduction above ULN if distal CMAP > 5 m V CMAP-
amplitude reduction of 1 m V if distal CMAP lower then 5 m V; 
7. distal CMAP-duration > ULN; 
8. increase ofCMAP-duration > ULN; 
9. distal CSNAP-amplitude < LLN; 
10. recruitment pattern 0 or SP; 
11. presence of denervation potentials. 
An electrodiagnostic variable was defined as abnormal if it fell outside limits of 
normal, which were based on a population of 45 healthy volunteers. We defined 
abnormal CMAP-amplitude reduction as being present if the observed CMAP-
amplitude decrease exceeded ULN; in cases where the CMAP-amplitude after 
distal stimulation was lower than 5 m V, we defined abnormal CMAP-amplitude 
reduction to be present if the difference between distal and proximal stimulation 
was at least I m V. Recruitment pattern was defined as abnormal if no pattern or a 
single pattern was obtained on maximal voluntary effort. 
In order to diagnose polyneuropathy on the basis of electrodiagnostic criteria, at 
least two different nerves were required to be abnormal. For a nerve to be conside-
red abnormal, at least three electrodiagnostic variables had to be abnormal (table 
8). Absent data may bias the findings towards a lower incidence of abnormal 
EMGs in the patient population as a whole. Therefore nerves in which only four 
electro diagnostic variables were tested were excluded, unless 3 or more variables 
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were abnormal; throughout the Results section the number of nerves tested is 
indicated. In addition, other numbers of abnormal variables were also applied and 
the resulting effect on the sensitivity and specificity was tested. The results of the 
first two EMGs were used to compute the sensitivity of neuropathy criteria, since 
these are only of relevance for early diagnosis. 
In addition to neuropathic criteria in general, the following findings, characteristic 
for demyelination, were evaluated: severe slowing of conduction, abnormal disper-
sion and abnormal CMAP-amplitude reduction (van der Meche et aI., 1988; Albers 
and Kelly, 1989; Brown, 1993). We defined signs of demyelination to be present in 
a peripheral nerve if at least one of the aforementioned criteria was fulfilled; two 
different levels of abnormality were tested (table 9 set A, set B). The poly-neuropa-
thy was considered to be demyelinating if two or more nerves showed signs of 
demyelination (table 9). The number of patients with sufficiently number of tested 
nerves is presented throughout the results section. In addition, we tested the sensiti-
vity of several previously designed sets of criteria for demyelinating polyn-
europathy in the same group of patients. Here again, a correction for bias due to 
absent values was performed and true incidence was calculated as the ratio be-
tween sufficiently tested patients and patients with electrodiagnostic abnormalities. 
Table 9. Criteria for primary demyelination. ULN upperlimit of normal; LLN 
lower limit of normal. 
SET A Proposed and tested set: I of the following abnormalities per nerve in at least 2 
nerves should be demonstrated: 
I. DML> 150%ofULN; 
2. m-NCV < 70% ofLLN ; 
3. F-wave latency> 150% ofULN; 
4. Abnormal CMAP-amplitude reduction> ULN. 
5. Abnomlal distal temporal dispersion: distal CMAP duration> 150% ULN; 
6. Abnormal temporal dispersion: distal to proximal CMAP duration ratio> 150% of 
ULN. 
SET B Proposed and tested set: I of the following abnormalities in at least 2 nerves 
should be demonstrated: 
I. DML> 300% ofULN ; 
2. m-NCV < 60% ofLLN ; 
3. F-wave latency> 150% ofULN; 
4. Abnormal CMAP-amplitude reduction> ULN. 
5. Abnonnal distal temporal dispersion: distal CMAP duration> 300% ULN; 
6. Abnormal temporal dispersion: distal to proximal CMAP duration ratio> 300% of 
ULN. 
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Table 10. Incidence of abnonnal nerves related to the required number of abnonnal variables within a nerve. 
EMGI EMGII 
uInar median peroneal > one nerve ulnar median peroneal > one nerve 
3 out of 5§ 88% (124) 90% (125) 70% (57) 85% (127) 93% (124) 93% (126) 77% (64) 93% (128) 
4 out of5§ 71 % (124) 78% (125) 39% (57) 64% (127) 81 % (123) 85% (126) 20% (55) 78% (127) 
50utof5§ 50% (124) 50% (124) 27% (56) 40% (126) 63% (123) 66% (125) 33% (51) 50% (125) 
5 out of7§ 53% (116) 52% (122) 30% (50) 42% (118) 64% (122) 68% (120) 37% (46) 53% (121) 
§ The first number gives the required number of abnonnal variables, the second the required number of evaluated variables. Between 
brackets the number of sufficiently tested patients. 
5.3 Results 
The median duration of weakness was 6, 13 and 28 days, respectively, at the 
moment of the 3 subsequent EMGs (table 2). 
I. At the first EMG most nerves were abnormal: ulnar nerve 88%, median nerve 
90% and peroneal nerve 70%. If criteria other than 3 abnormal variables out 
of at least 5 variables tested were applied, the yield of abnormal nerves was 
generally lower (table 10). The same trend was observed in the second EMG, 
but here the incidences were higher. In the 45 normal subjects these per-
centages were always zero. 
The diagnosis of a polyneuropathy, defined as having at least two abnormal 
nerves was made in 85% after the first EMG and in 93% after the second 
EMG. Again applying other criteria yielded lower results. None of the normal 
volunteers had electrodiagnostic signs of polyneuropathy (table 10). 
Table II. Incidence of motor nerves with at least one sign of demyelination. 
SETA 
ulnar nerve 
median nerve 
peroneal nerve 
two or more 
nerves 
SETB 
ulnar nerve 
median nerve 
peroneal nerve 
two or more 
nerves 
normal 
controls 
9% (45) 
7%(45) 
1!% (45) 
0% (45) 
normal 
controls 
9% (45) 
7% (45) 
9% (45) 
0% (45) 
EMGI 
54% (124) 
72% (120) 
51% (53) 
60% (124) 
EMGI 
33% (124) 
46%(120) 
38% (53) 
27% (124) 
EMGII EMG III 
69% (121) 74% (109) 
75% (130) 68% (130) 
52% (50) 56% (39) 
66% (124) 72% (109) 
EMGII EMG III 
44% (121) 49% (109) 
51%(130) 41%(130) 
38% (50) 15% (39) 
36%(124) 34% (109) 
Set A: [fane of the following is true DML > 150% ofULN; NCV < 70% ofLLN; F-Iat > 
150% of ULN if m-NCV is within normal limits; abnormal CMAP-amplitude reduction 
(see methods); temporal dispersion> 150% ULN). Between parenthesis the number of 
sufficiently tested nerves. 
Set B : [fone of the following is true DML > 300% ofULN; NCV < 60% ofLLN; F-Iat > 
150% of ULN if m-NCV is within normal limits; abnormal CMAP-amplitude reduction(see 
methods); temporal dispersion> 300% ULN). 
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II. Evidence for demyelination, as defined by criteria in set A, was seen in 54%, 
72% and 51 % in the ulnar, median and peroneal nerves, respectively, in the 
first EMG. In 60%, signs of demyelination were present in at least two nerves 
simultaneously (table II). If criteria were more stringent, as in set B, the yield 
for individual nerves was 33%, 46% and 38%, respectively, and for at least 
two nerves only 27% (table II). In subsequent EMGs these incidences increa-
sed maximally with an additional 17%. None of 45 healthy volunteers had 
signs of demyelination in more than one nerve according to the sets A or B. 
III. Applying previously published criteria for primary demyelinating polyneuro-
pathies, yielded rather low incidences at the first EMG, varying from 3% to 
22%, and at the third EMG, 13% to 46% (table 12). 
Table 12. Incidence of demyelination according to previously published sets of 
criteria. 
EMGI EMGII EMG III 
Albers and Kelly 5% (122) 11% (117) 15% (104) 
(1989) 
Asbury and Corn- 22% (74) 39% (57) 46% (63) 
blath (1990) 
Barohn et al. (1989) 3% (119) 8% (116) 13% (101) 
Between parenthesis the number of sufficiently tested nerves. 
5.4 Discussion 
We designed a set of electro diagnostic criteria for detection of polyneuropathy 
and a set for detecting signs characteristic of demyelination, and applied these in 
135 patients with clinically defined GBS. This is the first study in which such a 
large group of patients has been followed prospectively according to a standard 
EMG protocol. During follow-up, in none of the patients the clinical diagnosis 
of GBS was falcified; it is assumed, therefore, that in the patients the diagnosis 
was correct. 
The first set for the diagnosis of polyneuropathy per se was compiled from 
electro diagnostic variables available from the test-protocol. Because the normal 
limits for these variables are based on 95th percentiles, the application of indivi-
dual variables would have a false positive rate of 5%, by definition. Therefore, the 
major advantage of requiring a minimal number of three abnormal variables per 
nerve in several nerves was, that the false positive rate was reduced to zero in all 
45 healthy individuals and therefore the specificity was 100%. The sensitivity of 
this set was tested in two EMGs, performed at the moment of entry (EMG I) and 
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one week later (EMG II); at an early stage of the disease. The number of variables 
per nerve, required for a nerve to be scored as abnormal, is chosen rather arbitra-
rily; however, different combinations all yielded a high incidence of poly-neuropa-
thy. The set which scored best was the one which required three abnormal varia-
bles in two different nerves (85% in the first EMG and 93% in the second EMG) 
(table 10). Ulnar and median nerves contributed slightly more than the peroneal 
nerve (about 88% , 90% and 70%, respectively, in the first EMG, table 10). No 
such sets of criteria are as yet not available in the literature for comparison. 
Electrodiagnostic criteria, usually applied for the detection of demyelination, are 
DML, m-NCV, F-Iat and CMAP reduction and duration ofCMAPs, because these 
variables are related to nerve conduction slowing and conduction block (Barohn et 
aI., 1989; Albers and Kelly, 1989; van del' Meche et aI., 1988; Brown and Bolton, 
1993; Albers et aI., 1985). In the present study, the threshold value, that would 
discriminate, had to be chosen rather arbitrarily, as has been done by others (Albers 
and Kelly, 1989; Asbury and Cornblath, 1990; Bromberg, 1991). Nevertheless, the 
present set A yielded a rather high incidence of signs of demyelination (60%, 66% 
and 72% in consecutive EMGs) (table 11). Again, ulnar and median nerves 
contributed most (table 9; Set A). If, in contrast, criteria were made more rigid, 
sometimes more rigid than proposed by others (Asbury and Cornblath, 1990; 
Albers and Kelly, 1989) then a lower yield of 27%, 36% and 34% in three conse-
cutive EMGs resulted (table 9; set B) (table 11). The cause of this lower yield lies 
in the fact, that many GBS patients have (near) normal m-NCVs (Brown and 
Feasby, 1984; Arnason, 1993) and, as a consequence, will escape detection if the 
limiting value of NCV is set at a lower value. We think, however, that set A is a 
very reasonable proposition to use for the detection of demyelination, but a firmer 
conclusion can only be drawn if this set of criteria has been tested in a group of 
patients with pure axonal disorders. 
If previously designed sets were applied to the GBS patients in the present study, a 
much lower yield resulted compared to our set A (table 12) (Albers and Kelly, 
1989; Barohn et aI., 1989; Asbury and Cornblath, 1990; Bromberg, 1991). Only in 
the second EMG, the criteria proposed by Asbury and Cornblath led to an inciden-
ce comparable to our rigid set B (39%). These sets of criteria may therefore be too 
strict for application in GBS. This may be explained by the fact that these sets were 
designed for chronic demyelinating neuropathies. In this group of patients, presu-
mably due to the long duration, demyelinating characteristics are often far more 
pronounced. Our study shows that criteria derived from CIDP are not sufficiently 
sensitive. The electrodiagnostic criteria for demyelination as suggested in this work 
should idealy be verified by histological studies; this is of course not feasable in a 
large group ofGBS patients. 
Several studies, have revealed the demyelinating nature of nerve pathology in GBS 
(Asbury et aI., 1969; Said a et aI., 1979; Sumner, 1981; Brown and Bolton, 1993). 
Feasby et al. (Feasby et aI., 1985) were able to relate conduction block to patho-
logical demyelination in nerve biopsies. Also, experimentally induced conduction 
block -whether mechanically (Denny-Brown and Brenner, 1944a) or inllnunologi-
cally (McDonald, 1963a) is associated with demyelination. These studies suggest, 
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that significant demyelination will be revealed by conduction block and conduction 
slowing. However, in a number of nerves these electrodiagnostic signs of demye-
lination are not found, despite the fact, that demyelination is suspected on the basis 
of clinical observations. This may occur where lesions are patchy along the nerve 
outside the segment which can be tested in routine studies. Furthermore, conducti-
on block in the thinner segment of motor fibers may be difficult to detect, as long 
as a small number of large alpha motor units with thick axons - the principal 
constituents of the CMAP - are free from demyelination. This has been demonstra-
ted by morphological and physiological studies (Feasby et a!., 1985; Brown and 
Bolton, 1993). Another reason why patients with demyelination may pass undetec-
ted using the proposed criteria, is that many GBS patients have a very low distal 
CMAP-amplitude (van del' Meche et a!., 1988). As other causes, like axonal 
degeneration or motor end plate dysfunction cannot be discriminated from distal 
demyelination, low CMAP amplitudes cannot be applied as a criterion of primary 
demyelination. Therefore, the patients with predominant distal demyelination, will 
escape detection and may, in any set, cause a serious underestimation of the inci-
dence of demyelination. 
In conclusion: in the 135 GBS patients studied, the proposed set of criteria for 
polyneuropathy had a sensitivity of 85% and a specificity of 100%. The polyneuro-
pathy was demyelinating in 72% or 36%, respectively, using two sets of criteria for 
demyelination. The less rigid set is proposed as the more reasonable, but should be 
tested in other categories of demyelinating and pure axonal neuropathies. 
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Chapter six 
Prognostic value of electro diagnostic testing in the Dutch 
Guillain-Barre trial 
6.1 Introduction 
The pathophysiological hallmark of the Guillain-Barre syndrome is demyelination 
in peripheral nerves, often followed by secondary axonal degeneration (Arnason, 
1993; Asbury et aI., 1969; Asbury, 1978b; Madrid and Wisniewsky, 1976; Said et 
aI., 1981). Demyelination causes conduction block resulting in clinical deficit, 
usually severe quadriparesis, sensory loss and a need for artificial respiration in 
about 20% of the patients. Electrophysiologically demyelination is reflected by 
lower amplitudes of evoked motor responses with conduction block and slowed 
conduction (Brown et aI., 1981; McLeod et aI., 1981; Brown and Feasby, 1984; 
Albers et aI., 1985; Kimura et aI., 1988; van der Meche et aI., 1988). Several 
studies have indicated that low CMAPs are associated with a poor clinical outcome 
(Gruener et aI., 1987; Cornblath et aI., 1988; McKahn et aI., 1988; Miller et aI., 
1988; Winer et aI., 1988). In these reports electrodiagnostic studies were not al-
ways performed at similar stages of the disease. In the Dutch Guillain-Barre trial, 
comparing the effect ofIgIv and PE in 147 Guillain-Barre patients (van der Meche 
et aI., 1992), 3 EMG's were planned: at entry, at one week and 4 weeks after entry 
into the trial. In this report we studied the predictive value of the electrodiagnostic 
findings for clinical recovery. 
6.2 Patients and methods 
147 Patients fulfilling the criteria ofGBS (Asbury et aI., 1981) were followed for 6 
months in the Dutch Guillain-Barre Trial, which was a randomised trial comparing 
IgIv and PE. In order to enter the study, patients had to be ill for less than two 
weeks and had to be unable to walk independently. Further details and results of 
this trial are described elsewhere (van der Meche et aI., 1992). 
Outcome criteria discussed in this paper are ability to walk independently 8 weeks 
and 6 months after entry into the trial. These moments were chosen for their clini-
cal relevance in the prognostic calculation. At 8 weeks patients can be divided into 
two groups of almost equal seize: a fast recovering group, able to walk indepen-
dently and a slow recovering group, not yet able to walk. The group that is unable 
to walk independently at 6 months is the group that may be left with considerable 
deficit. An additional outcome criterion that will be discussed is how much time is 
needed to be able to walk independently again. 
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Electrodiagnostic testing was performed by experienced clinical neurophysiolo-
gists, all members of the Dutch Guillain-Barre Study Group in temperature con-
trolled rooms, using standardised conventional techniques. 
Ulnar and median motor and sensory nerves were tested and the peroneal motor 
nerve was facultatively tested. Motor nerve conduction velocities, distal motor 
latencies and CMAPs were obtained after distal and proximal stimulation (i.e. wrist 
and elbow, ankle and knee). Nerve conduction velocities were corrected for tempe-
rature effects (Dejesus et aI., 1973; Geerlings and Mechelse, 1985). Minimal F-
response latency was determined after 20 stimuli applied distally. Utmost care was 
taken to stimulate nerves supramaximally and to search for the maximal CMAP 
above the muscle belly with surface disk electrodes in the tendon-belly montage. 
CMAP-amplitudes of the hypothenar, thenar and extensor digitorum brevis mu-
scles were measured peak to peak, as well as the duration of the negative phase. 
Myography was performed using concentric needle electrodes in abductor pollicis 
brevis (M. APB), abductor digiti quinti (M. ADV) and anterior tibial muscles (M. 
TA). The presence and density of positive sharp waves and fibrillation potentials 
(denervation potentials) were estimated as follows: 0 = not present; I = a few 
present; 2 = many denervation potentials, but baseline not completely filled; 3 = 
many denervation potentials and baseline completely filled. Recruitment pattern on 
maximal voluntary effOlf was also tested and estimated as follows : interference 
pattern (IP) = normal i.e. full pattern; mixed pattern (MP) = moderate decreased 
pattern; single pattern (SP) = severe decreased pattern; 0 = no motor unit potenti-
als recognisable. 
Electrodiagnostic testing was scheduled within two days after entry into the trial, at 
one week and one month after entry. The results of the second EMG are emphasi-
sed here to study prognostic value because the majority of patients were in their 
nadir at this point, whereas at entry patients were in various stages of progression. 
Data collected fi'om the first and third EMG were used to study diagnostic criteria 
and axonal degeneration, respectively; the results will be published separately. 
We studied correlations between clinical outcome criteria and electl'Odiagnostic 
parameters that consisted of continuous variables (CMAP-amplitudes, distal / 
proximal ratio of CMAP-amplitudes (CMAP-ratio), difference between CMAP 
amplitude after distal and proximal stimulation (CMAP-difference), distal motor 
latency, motor nerve conduction velocities). In contrast, the recruitment pattern 
was dichotomised into groups with grade 0 or SP and grade MP or IP. Also, densi-
ty of denervation potentials for individual muscles was dichotomised into groups 
with grade 0 or 1 and grade 2 or 3. A single general variable for the presence of 
denervation activity was determined for the three muscles studied. If no denervati-
on was ever found in any muscle, we used to term "absent"; if denervation, scored 
at grade 2 or 3, was found in more than one muscle, we called it "abundant", and 
all the findings in between were categorised as "moderate". 
The data obtained one week after entry were used to develop a prognostic model. 
All electro diagnostic data were dichotomised according to the observed statistical 
median for reasons of clinical applicability. Differences in proportions between 
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groups were tested with the chi-square test. With the variables that yielded signifi-
cant results in univariate analysis, a multivariate analysis was performed to see 
which set of variables obtained were predictive of ability to walk independently 8 
weeks and 6 months after entry. 
6.3 Results 
6.3.1 Efficacy of follow-up schedule 
The mean time interval from entry to the three EMGs was in accordance with the 
schedule of the trial protocol (table 13). The number of missing data are not parti-
cularly confined to one functional grade in any of the three EMG's. As a group, 
patients in whom a second EMG was not performed, were not different from the 
group of tested patients. Median time-interval from onset of the weakness until the 
second EMG was 13 days (inter 5% - 95% percentile range: 9 to 22 days). Most of 
the patients (87%) were at the nadir of their disease at that time. 
Table 13. Time of EMG and number of studies compared to the protocol in 147 
patients. 
DAYS AFTER ENTRY NUMBER OF PA TlENTS STUDIED 
scheduled observed 
EMG median range 
, 
ulnar median ant.tib. 
first EMG 125 124 56 
second EMG 6-8 8 6-12 125 127 55 
third EMG 26-30 29 24-40 113 117 47 
, Inter 5%-95% percentile range. 
6.3.2 Correlation of electrodiagnostic findings with clinical recovery 
In general, group average CMAP-Gmpliludes obtained with distal stimulation as 
well as with proximal stimulation of the ulnar nerve, were significantly higher if 
patients could walk independently 8 weeks and 6 months after entry, compared to 
patients unable to walk, although substantial overlap did occur (fig. 7). This was 
the case for all consecutive EMGs. Similar results were found in other motor 
nerves again in all EMGs (p = 0.0001 for both median nerve and for peroneal 
nerve in the second and third EMG). CMAP-amplitudes obtained with distal 
stimulation showed a significant negative correlation with time needed to walk 
independently (Spearman-Rank). Moreover, in all three tested nerves, the strongest 
correlation was always found in the third EMG (table 14). If CMAP-amplitudes 
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obtained in individual patients were summed no stronger correlations were obtai-
ned. Seven patients showed absent CMAPs after distal stimulation of the ulnar 
nerve in the second EMG. None of them was able to walk independently 2 months 
after entry and only 2 patients 6 months after entry. 
Table 14. Correlation of time until independent locomotion and CMAP amplitudes 
(Spearman). 
M.ADV M.APB M.EDB 
EMG rho p rho p rho p 
first EMG -.28 0.0016 -.15 0.095 -.18 0.17 
second EMG -045 < 0.0001 -AI <0.0001 -.46 0.0004 
third EMG -.56 < 0.0001 -.50 < 0.0001 -.70 < 0.0001 
M. ADV abductor digiti millimi muscle; M. APB abductor pollicis brevis muscle; M. EDB 
extensor digitorum brevis muscle. rulO =: correlation coefficient (Spearman). 
Decreased ratios of CMAP-amplitudes and absolute differences between CMAPs 
obtained with proximal and distal stimulation indicate demyelination between the 
stimulation sites. However, such ratios or differences did not correlate with any 
outcome measure in any EMG. 
Average distal motor latencies or minimal F-response latencies of the three nerves 
obtained in any of three EMGs did not differ significantly between the outcome-
groups. The average motor conduction velocities in the forearm segments of ulnar 
and median nerves were significantly lower only in the second (p < 0.05) and in 
the third EMG (p < 0.005) in the groups unable to walk independently at 8 weeks. 
However, these results were not found for independent locomotion at 6 months. 
Recruitment pattei'll on maximal voluntary effort showed a positive correlation 
with outcome 8 weeks and 6 months after entry, especially in the second and third 
EMGs. Time needed to walk independently was significantly shorter if the recruit-
ment pattern was better (table 15). 
In most of the patients in whom denervation activity developed, the density of 
denervation potentials was maximal in the third EMG. If denervation potentials 
were always absent in any muscle there was a 93% chance that patients were able 
to walk independently 6 months after randomisation (Chi square p < 0.001). If 
abundant denervation activity was present (denervation activity grade 2 or 3 accor-
ding to the semiquantitative score in at least two muscles in any EMG), there was 
only a 47% chance of walking independently 6 months after randomisation (Chi 
square p < 0.001). Furthermore, significantly more time was needed to achieve 
independent locomotion than in the group without denervation activity (table 16). 
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INDEPENDENT WCOMOTION 6 MONTHS AFTER ENTRY 
Fig. 7. CMAP amplitudes of hypothenar muscle after distal stimulation ofthe ulnar nerve in 
all three EMGs in patients able (A) or unable (N) to walk independently 8 weeks (upper 
figure) and 6 months (lower figure) after entry, respectively. Bars indicate median value 
and inter 5% to 95% percentile ranges of CMAP-amplitudes and significance level of 
difference between outcome groups at each EMG (Mann-Whitney test). 
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Table 15. Proportion of patients able to walk independently related to recruitment 
pattern in M. ADV. 
% with independent Days until independent 
locomotion at: locomotion: 
Pattern 8 weeks 6 months mean SO number 
IP 88% 100% 34 49 8 
MP 66% 87% 57 55 53 
SP 42% 84% 92 60 31 
0 7% 21% 166 39 14 
p-value 0.00 0.00 0.00 
Proportion of patients able to walk independently 8 weeks and 6 months after entry and the 
number of days needed to reach this stage related to recmitment pattern on maximal volun-
tary effort in M. ADV obtained at the second EMG (see methods). 
Table 16. Proportion of patients being able to walk independently related to the 
general score of density of denervation potentials. 
% with independent days until independent 
locomotion at: locomotion: 
density 8 weeks 6 months mean SO number 
absent 70% 93% 55 56 43 
moderate 40% 72% 97 64 40 
abundant 23% 47% 126 67 30 
p-value 0.001 0.001 0.001 113 
Proportion of patients being able to walk independently 8 weeks and 6 months after entry 
and the number of days needed to reach this stage related to the general score of density of 
denervation potentials as defined from all three EMG's (see methods). 
6.3.3 Multivariate analysis of prognostic factors 
As a preparation for multivariate analysis, univariate analysis was performed using 
dichotomised values of electrodiagnostic data obtained one week after entry (se-
cond EMG). Most of the patients (87%) were at the nadir of the disease at that 
time. The CMAP-amplitudes obtained after distal and proximal stimulation of 
ulnar and median nerves and recruitment pattern in all three tested muscles again 
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proved to be significant predictors for outcome 8 weeks and 6 months after entry. 
In addition, m-NCV and DML of ulnar and median nerves now appeared to be 
weak but significant predictors for outcome at 8 weeks only (table 17). 
Table 17. Univariate analysis of electrodiagnostic tests of the second EMG in 
relation to the ability of independent locomotion at 8 weeks. 
factor 
Hypothenar CMAP 
distal stimulation 
Hypothenar CMAP 
proximal stimulation 
DML ulnar nerve 
Motor NCV forearm 
ulnar nerve 
Motor NCV upperarm 
ulnar nerve 
Recruitment pattern 
M.ADV 
Thenar CMAP 
distal stimulation 
Thenar CMAP 
proximal stimulation 
Recruitment pattern 
M.APB 
Recruitment pattern 
M.TA 
ceasura 
<4mV 
>=4mV 
< 4mV 
>~4mV 
>~4mSec 
< 4 mSec 
< 60 In/sec 
>= 60 m/sec 
< 50m/sec 
> ~ 50 In/sec 
OorSP 
MP or IP 
<4mV 
>~4mV 
<3mV 
>~3mV 
o or SP 
MP or IP 
o orSP 
MP orlP 
improved 
13 (25%) 
50 (68%) 
24 (39%) 
38 (67%) 
17 (41%) 
47 (61%) 
33 (47%) 
31 (66%) 
12 (43%) 
28 (67%) 
14 (31%) 
43 (70%) 
25 (39%) 
39 (62%) 
23 (40%) 
41 (64%) 
15 (33%) 
44(71%) 
9 (31%) 
16 (64%) 
not 
improved 
39 
24 
37 
19 
24 
30 
37 
16 
16 
14 
31 
18 
39 
24 
34 
23 
30 
18 
20 
9 
dif' p-value 
43% 0.000 
28% 0.003 
20% 0.042 
21% 0.045 
24% 0.049 
39% 0.000 
23% 0.010 
24% 0.009 
38% 0.000 
33% 0.Ql5 
improvement percentage for second category minus improvement percentage for first 
category. 
Multivariate analysis did not select a restricted number of variables important to 
predict independent locomotion at 6 months. However it yielded two factors which 
contributed independently to the outcome of independent locomotion at 8 weeks 
after entry : hypothenar CMAP-amplitude after distal stimulation and recruitment 
pattern of the abductor digiti minimi muscle (table 18). These results were inde-
pendent of the kind of therapy used (Le. Ivlg or PEl. Age appearde to have a weak 
effect on both outcome measures. These two parameters may be used to predict 
outcome in individual patients. If at the nadir of the disease the CMAP amplitude 
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is below 4 mY and the pattern is worse than MP, the chance for independent 
walking 8 weeks after entry is 20%. If, on the contrary, CMAP amplitude exceeds 
4 mY and the pattern is better than MP, this chance is 78% (table 19). 
Table 18. Multivariate analysis of electrodiagnostic tests of the second EMG in 
relation to the ability of independent locomotion at 8 weeks. 
Factor Logistic coef. SE p-value 
Hypothenar distal 1.53 0.47 0.002 
CMAP 
Recruitment pattern 1.11 0.47 0.002 
M.ADV 
Table 19. Predictive value of Ulnar ADV distal CMAP and recruitment pattern of 
ADV (2-nd EMG). 
Ulnar ADV distal recruitment chance for independent 
CMAP pattern of ADV walking at 8 weeks 
<4mV <mp 20% 
<4mV >=mp 43% 
>=4mV <mp 53% 
>=4mV >=mp 78% 
The chance for independent locomotion at 8 weeks is given by the formula: 
p = I/(J+exp (- (-1.39 + 1.53*a + 1.11*b»); a = 0 ifCMAP < 4 mY, else a = 1; 
b"" 0 if recruitment pattern is worse then mp, else b = I. 
6.4 Discussion 
When comparing the EMG at entry, at one week and at four weeks, the second 
EMG is considered to be the most valuable for prognostic asessmenl. On the one 
hand, the results obtained in the second EMG correlated better with outcome 
compared to the first EMG. This can be explained by the fact that at that moment, 
most of the patients (87%) were at the nadir of the disease. At the other hand, 
compared to the timing of the third EMG, the second EMG was still sufficiently 
early to make a prognostic evaluation useful (median time 13 days). Our first 
conclusion is, therefore, that prognostic evaluation using electrodiagnostic means 
can best be done at the early nadir of the disease. 
Abnormally low CMAP amplitudes, obtained during the nadir, with distal as well 
proximal stimulation are associated with a poor outcome. These findings are in 
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accordance with previous prospective studies (Ropper et aI., 1986; Gruener et aI., 
1987; Cornblath et aI., 1988). This correlation is, however, weak. The variation in 
distal ulnar CMAP at the nadir explains only 20% (i.e. rho square) of the variation 
in time until independent locomotion. From the scatter plot (fig. 7), it is also obvi-
ous that in individual patients, low CMAP amplitudes are often not associated with 
slow recovery. This can also be inferred from comparable plots in other reports 
(Gruener et aI., 1987; Miller et aI., 1988). This wide variation may be explained by 
several factors. If low CMAP amplitudes are caused by distal demyelination, as 
might occur in a subgroup of Guillain-Barre patients, fast recovery is more likely 
to occur than in cases where low amplitudes are caused by axonal degeneration 
(van der Meche et aI., 1988, 1991). In addition, axonal damage may be confined to 
terminal motor twigs (Asbury et aI., 1969; de Waal, 1990). In such cases, fast 
recovery may be expected in contrast to cases in whom the entire axon is damaged. 
Unfortunately, these causes of low CMAP amplitudes cannot be separated by 
conventional electrodiagnostic testing. Moreover, falsely low CMAP-amplitudes 
may be found, due to incorrectly placed electrodes or submaximal stimulation of 
less excitable nerves. This was, however, anticipated and avoided in the present 
study by means of a rigid protocol. On the other hand, if high CMAP-amplitudes 
with distal stimulation are found, technical errors are less likely. However, patients 
with high CMAP-amplitudes at the nadir, may still recover slowly (fig. 7). Possible 
explanations are the variability in distribution of weakness over proximal and distal 
muscles, and the occurrence of more secondary axonal degeneration in the lower 
compared to the upper limbs. Moreover, it is difficult to judge in individual pa-
tients the extent to which the CMAP has decreased. Hypothenar CMAP amplitudes 
can be as high as 30 mY in healthy individuals; a dramatic fall in amplitude of 25 
mY, would still leave a relatively high amplitude of 5 mY. We are, therefore, 
inclined to be cautious about the short-cut that a hypothenar CMAP-amplitude 
after distal stimulation bears a simple relationship to prognosis in an individual 
patient. Absent CMAP-amplitudes after distal stimulation were associated with 
poor recovery and probably indicates more extensive degeneration of the axons. In 
. such cases recovery will take longer (Triggs et aI., 1992; van der Meche et aI., 
1988,1991). 
Evidence for axonal degeneration as indicated by denervation potentials has been 
associated with a grave prognosis (McLeod, 1981; Brown and Feasby, 1984; 
Feasby et aI., 1986; Gruener et aI., 1987; Miller et aI., 1988; van der Meche et aI., 
1991). In our study, however, we found that the presence of abundant denervation 
potentials is not always associated with a poor prognosis, as reported previously 
(Ropper et aI., 1986; Ropper et aI., 1990). First of all this may be caused by the 
fact that the number of damaged axons is not necessarily reflected by the density of 
denervation potentials. For instance, density of denervation potentials may show 
fluctuations according to temperature. Secondly, if axonal degeneration is confined 
to terminal motor twigs, recovery is likely to be much faster compared to degenera-
tion of the entire axon. 
In the present study, recruitment pattern on marimal voluntmy contraction obtai-
ned early in the course of the disease was found to have a significant predictive 
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value. This variable reflects general nerve fuction. It would be altered by axonal 
degeneration as well as by conduction block anywhere along the nerve. This test 
particularly contributes to the assessment of proximally located nerve segments, 
which can hardly be tested by the use of the CMAP-amplitude as a parameter. 
Moreover, the recruitment pattern is not influenced by the effects of large variation 
in individual normal values, as is the CMAP amplitude. 
The CMAP-ralio had no predictive value and this is in agreement with other stu-
dies (Cornblath et aI., 1988). The ratio between proximal and distal CMAP-ampli-
tudes is an important physiological measure as it reflects conduction block. Since 
conduction block can be quickly restored, one might expect that a lower ratio 
indicates a good potential for recovery. That this is not true, may be explained by 
the fact that the ratio is independent of the absolute amplitude. For instance: an 
amplitude of 5 m V and 10m V after proximal and distal stimulation, respectively, 
will result in a CMAP-ratio of 0.5; but amplitudes of 0.5 mV and I mY, respecti-
vely, give the same ratio, which evidently has different implications (van del' 
Meche et aI., 1985). Furthermore, the problem with the CMAP ratio is, that it not 
exclusively reflects conduction block, but is influenced also by abnormal dispersi-
on. It is very likely, that abnormal dispersion, like m-NCV (see below) is only very 
weakly related to outcome. (Sumner, 1981, 1992; Olney et aI., 1987; Kimura et aI., 
1988; van del' Meche et aI., 1988; Rhee et aI., 1990). Absolute differences in 
CMAP amplitudes between distal and proximal stimulation sites, however, did 
neither have prognostic value. 
We found only a weak correlation between lIlolor-NCV in forearm nerve segments 
and outcome. Several previous studies showed conflicting results (see 13 for 
review). In many severely paretic GBS patients, a normal NCV may be found in 
the acute phase (Brown and Feasby, 1984; Albers et aI., 1985; Ropper et aI., 1986), 
whereas conduction slowing often tends to occur later, possibly as a result of de-
and remyelination. 
Similar arguments account for the limited value of F-response lalencies with 
regard to outcome prediction. Only a very few intact axons can preserve the pre-
sence of normal F-responses. 
The prognostic value of distal CMAP amplitudes was reduced when adding other 
prognostic factors in multivariate analysis, like age, duration of illness, artificial 
ventilation, fuctional score at entry, presence of campylobacter infection and GM I 
antibodies (van del' Meche et aI., 1991). This indicates, that the CMAP is just one 
of the parameters that reflects severity of weakness. 
6.5 Conclusion 
For prognostic evaluation in GBS, needle electromygraphy and nerve conduction 
studies may best be performed as soon as the nadir has been reached. Recruitment 
pattern on maximal voluntary effort and hypothenar CMAP amplitudes after distal 
stimulation are the best singular predictors of outcome. 
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Chapter seven 
Axonal degeneration in Guillain-Barre syndrome 
7.1 Introduction 
The diagnosis of the Guillain-Barre syndrome is made on the basis of generally 
accepted criteria, the most important being progressive symmetrical paresis and 
decrease of myotatic reflexes (Asbury, 1981). Demyelination resulting in conduc-
tion failure is the cause of the paresis (Arnason, 1993). In later stages of the disea-
se, however, axonal degeneration may be observed in some patients. In general, it 
has been suggested that axonal degeneration is a bystander effect of demyelination 
in which the axon is the innocent victim of a fulminant attack on its myelin (Ma-
drid and Wisniewsky, 1976; Said et aI., 1981; Arnason, 1993). On the other hand, 
a primary axonal form of GBS has recently been proposed (Albers et aI., 1985; 
Feasby et aI., 1986). Conduction block is the physiological hallmark of demyelina-
tion. If demyelination is followed by severe axonal degeneration evidence for 
conduction block should be followed by very low or absent CMAPs and denervati-
on potentials in serial EMG studies. However, the description of such longitudinal 
EMG studies in individual patients are lacking. In the present report we describe 
eight patients who developed clinical and EMG evidence of axonal degeneration. 
7.2 Patients and methods 
Between July 1985 and the end of 1987, 42 GBS-patients, both primary and secon-
dary referrals, were seen in our department. Eight patients fulfilled the following 
criteria for severe axonal degeneration: I) the presence of denervation potentials; 
2) at least one inexcitable nerve and 3) slow clinical recovery (table 20). Patients 2, 
4-6, 8 and 9 took part in the Dutch multicentre trial comparing high dose intrave-
nous immune globulin (IgIv, GammagardR-Baxter, Hyland division) with plasma 
exchange, which explains the different specific treatment modalities in table 20 
(Kleyweg et aI., 1988). The physiological techniques were similar to those previ-
ously published (van del' Meche et aI., 1988). In all patients median, ulnar and 
peroneal nerves were investigated at least on admission, and one week and one 
month later. Stimulus parameters were increased until maximal responses were 
obtained. Motor fibers were studied by recording with surface electrodes from m. 
abductor pollicis brevis (APB), m. abductor digiti quinti (ADY), m. tibialis anterior 
(TA) and m. extensor digitorum brevis (EDB); sensory fibers by recording 
antidromic ally from the second and fifth fingers respectively. The latencies and the 
peak/peak amplitudes of both the sensory nerve action potentials (CSNAP) and the 
CMAPs were measured. The duration of the negative phase of the CMAP was 
measured to study differential dispersion. For APB and ADV differential dispersi-
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Table 20. Clinical characteristics 
Patient 2 3 4 5 6 7 8 
Age 66 74 72 30 56 45 51 46 
Sex M M M M M M M M 
Days until nadir 5 5 9 11 8 9 5 5 
Nadir Quadriplegic Quadriplegic Quadriplegic Quadriplegic Almost Quadriplegic Quadriplegic Almost 
quadriplegic'" Quadriplegic· 
Period on respi- 0 6 months 3 months 3.5 months 1.S months 7 months 7 months 0 
rater 
Function after 6 walks with Deceased Chair-bound Bedridden Chair·bound On respirator On respirator Walks with sup-
months support pert 
Specific treat- Igiv PE PE PE None PE None IgIv 
ment 
• Some muscles grade 1 or 2 (MRC) 
on was defined as an increase in duration of the negative peak by more than 8%, 
when stimulation was carried out at the elbow rather than at the wrist (Brown and 
Feasby, 1984). "Length. dependent CMAP reduction" was defined as a more than 
10% decrease in the peak·peak amplitude when proximal was compared with distal 
stimulation. In the absence of differential dispersion this can be ascribed to 
conduction block (Brown and Feasby, 1984; Kimura et aI., 1986). 
For needle myography the following semi·quantitative scoring system was used to 
describe the presence of fibrillation potentials and positive sharp waves: O:not 
present; +:present; ++ many denervation potentials but baseline not filled; +++: 
baseline completely filled. 
7.3 Results 
All 8 patients were male; their ages ranged from 30 to 72 years (table 20). 
All showed denervation potentials and low CMAPs or inexcitable nerves at some 
stage of the disease (table 21). They could, however, be divided into two groups on 
the basis of the findings in the first physiological examination. Patients 1-5 showed 
clear evidence of "Iength·dependent CMAP reduction" and patients 6-8 already 
had low CMAPs in the first study. 
Patients 1-5. In the first study all these patients showed considerable length·depen-
dent CMAP and amplitude reduction, i.e. the CMAP decreases with more proximal 
stimulation. The lack of differential dispersion tends to indicate conduction block 
along the length of the nerve. At the nadir, however, many of the nerves became 
inexcitable or showed very low CMAPs without length·dependent amplitude 
reduction (table 21). Two patients are presented in more detail. 
Patient 1 demonstrates the general pattern. In the first study (fig. 8a) he showed 
conduction block; at this time he had already become quadriplegic. No further 
clinical deterioration occurred until the next study (fig. 8b). At that time, however, 
the ulnar nerve had become inexcitable and the median and peroneal nerve showed 
extremely low amplitudes without length· dependent amplitude reduction (table 
21); at the same time abundant denervation potentials became apparent. Recovery 
was slow and incomplete over a period of 18 months. In this patient the sensory 
system was normal both clinically and physiologically throughout the course of the 
disease (table 21). 
Patient 5 showed conduction block followed by severe axonal degeneration in only 
some of his muscles, especially those of his right leg. Initially motor deficit was 
symmetrical but during improvement the right leg lagged behind and this resulted 
in a prolonged rehabilitation period. The clinical discrepancy was reflected in the 
discrepancy between the CMAPs of APB and EDB or TA, respectively. Denervati-
on potentials were also abundant in the right leg in contrast to APB. This patient 
demonstrates that the length·dependent amplitude reduction present in several 
nerves can be followed by severe axonal degeneration in only some of them. 
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Fig. 8. CMAPs obtained in m. abductor pollicis brevis after stimulation of the median nerve 
at three levels, four (A) and eleven days (8) after onset of weakness. The patient was 
quadriplegic on both days. Note the different amplification scales. 
Patient 6-8. The CMAPs were already low in the first study. Some length-depen-
dent CMAP reduction could be demonstrated (table 21). This could not be explai-
ned in any case by dispersion of the amplitude comparing distal and proximal 
stimulation. These findings suggest, therefore, that some conduction block was 
present (Brown and Feasby, 1984). At the nadir these patients did not differ clini-
cally from patients 1-5. 
The sensDlY system (all patients) 
The sensory system was unaffected clinically and not or minimally physiologically 
in 3 patients (nos. 1, 7, 8,). In two more patients (nos.2 and 6) the sensory system 
became involved at a later stage, but was relatively spared as shown by the presen-
ce of small CSNAPs in nerves from which a motor response could no longer be 
obtained. In 3 patients (nos.3-5), all with conduction block in the motor nerves, the 
sensory system was involved both clinically and physiologically. 
7.4 Discussion 
Eight Guillain-Barre patients have been described, who developed severe axonal 
degeneration of the motor fibers. Although axonal degeneration is best determined 
by morphological criteria, this is in general not feasible in GBS-patients. Electrop-
hysiological evidence of axonal degeneration, denervation potentials and CMAP 
decrease, is the second best parameter for axonal degeneration, but does not discri-
minate between degeneration of terminal nerve twigs and loss of complete axons. 
Moreover, distal demyelination can result in CMAP decrease just like axonal 
degeneration. This might occur in a subgroup of GBS patients (van der Meche et 
aI., 1988). In the present study it was aimed to include only patients with severe 
loss of the motor axons and therefore the prerequisites were: 1. presence of dener-
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vat ion potentials, 2. absent CMAP in at least some nerves and 3. slow clinical 
recovery suggestive of axonal regeneration. 
The progress from early lesions to severe axonal degeneration was followed by 
means of longitudinal EMG studies. In the majority of patients (nos. 1-5) the first 
study was characterised by significant conduction block. This was concluded from 
a "Iength-dependent CMAP amplitude reduction" of more than 25% without 
evidence for differential dispersion of the duration of the CMAPs. These findings 
are explained by lesions scattered along the nerve. From combined physiological 
and anatomical studies it was concluded that the causative lesion is demyelination 
(Feasby et aI., 1986). Our observations suggest therefore, that in these patients 
demyelination occurred first and that this was followed by axonal degeneration. A 
further supportive argument for primary demyelination is that in other GBS-pa-
lients a similar conduction block has been observed, followed by rapid and com-
plete recovery without the development of axonal degeneration (Brown and Feas-
by, 1984; van der Meche et aI., 1988). Finally, observations in patient 5 demonstra-
ted that conduction block can be followed by fast recovery in a part of the body 
(arms and left leg) suggestive of de- and remyelination while in another part (right 
leg) of the body of the same subject it can be followed by severe axonal degenera-
tion. This observation makes it very likely that the initial lesion was also demyeli-
native in the extremity with axonal degeneration. 
In a minority of patients (nos.6-8) only minimal conduction block could be detec-
ted and the CMAPs were already low in the first study. In these cases several 
mechanisms can be proposed: 1. the process is similar to the process in patients 1 -
5, but is more advanced at the time of the first EMG study; 2. distal demyelination, 
which has been suggested to occur in a group of GBS patients (van der Meche et 
aI., 1988), is followed by axonal degeneration; 3. primary distal axonal degenerati-
on occurred. 
In general, it can be said that the processes determined in all patients can be explai-
ned by the same pathophysiological patterns as described before (van der Meche et 
aI., 1988). Axonal degeneration might just reflect a more severe course of the 
disease. Also in experimental models of inflammatory polyneuropathy, it has been 
shown that a demyelinating mechanism may result in axonal degeneration in a 
dose dependent manner (Hartung et aI., 1988). Alternatively, in these severely 
afflicted patients an additional "axonal" factor may be present, resulting in wide-
spread axonal degeneration and contributing to conduction block. The possibility 
of a pure axonal mechanism has been suggested (Feasby et aI., 1986), after study-
ing 5 exceptionally severe GBS-patients. At the time of their first EMG's, however, 
the nerves were already inexcitable. Therefore, it is feasable that they may have 
missed an earlier demyelinating stage of the disease. Their one autopsy case, 
however, is very suggestive of primary axonal degeneration, although axonal 
degeneration following fulminant demyelination is difficult to exclude. This latter 
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Table 21. EMG studies of median, ulnar and peroneal nerve. W-res: worst result measured at either of the 3 studies.~ MRC: 
force measured according to the Medical Research Council Scale. 
Patient 2 4 S 6 7 
1st study W-res* 1st study W.res'" 1st study W-res· 1st study W-res'" 1st study W-res· 1st study W-rcs'" 1st stud)""W res· 1st study W-res'" 
Day after onset 4 II 4 12 4 13 33 7 40 5 12 7 ,4 
Median nerve 
APB (MRC)'l) 0 0 0 0 4 3 0 2 0 0 0 0 
CMAP-wrist (mY) 7.6 020 9.4 0 6.0 035 42 0 8.0 2.3 225 0 0.7 0 0 
CMA.P-elbow (mY) 0.75 O.lS 13 0 5.2 020 3.0 0 4.0 025 1.75 0 03 0 0 
Dr.1L (msec) 3.0 2.7 3.6 3.9 6.7 5.7 0 3.1 8.9 3.9 0 3.4 0 0 
NCV (m/sec) 62 54 44 57 28.4 54 0 47 34 63 68 0 
CSNAP-wrist{uV) 18 IS 17 4 0 0 0 IS 0 20 10 34 20 IS 
CSNAP-elbow (uV) 11 8 7 2 0 0 0 0 0 0 10 5 16 7 5 
Ulnarnerve 
ADV (MRcrI 0 0 0 0 4 0 3 0 0 2 0 0 0 0 
CMAP-wrist (mY) 0 7.1 0 9.6 0.75 5.4 0 10.8 0.75 4.0 0 0 1.0 
CM-\.P-e!bow (mV) 0.4 0 3.6 0 8.1 0.75 23 0 5.1 0.65 4.0 0 0 0.8 0 
CMAP-axiUa emV) 0.04 0 0.9 6.0 1.' 0 42 0 0 0.5 0 
DML(msec) 33 2.9 3.2 72 4.0 0 22 7.4 3.6 0 0 2.4 0 
NCV (m/sec) 54 60 0 68 28.3 43 0 4S IS SO 0 0 62 0 
CSNAP-wrist{uV) 17 18 11 2 0 0 20 10 22 20 IS 
CSNAP-elbow (uV) 10 6 0 0 0 0 0 0 IS 9 10 
CSNAP-nx.illa euV) 5 0 0 0 0 0 7 6 
Peroneal nerve 
CM-\P-EDB-ankJe 2.5 0.4 0 0.8 0 1.0 0 1.8 0 3.8 0 0.13 4.5 0.5 
(mY) 
CM-\P-TA-Icnee 0.5 0 03 0 
(mY) 
DCIlervation APB++ APB++ APB++ APB APB+ APB+++ APB++ APB+++ 
+++ 
Biceps ADV++ TA+ ADV+ U+++ TA+++ TA++ TA+++ 
++ 
TA++ TA++ TA+ Q+++ 
Q++ 
order of events has also been described recently in another autopsy case (Kanda et 
aI., 1989). In our cases 6-8 we included a pure axonal form as the third option. 
No sensory impairment, either clinically or physiologically was observed in pa-
tients 1,7 or 8; a marked discrepancy was present in patients 2 and 6. Sparing of 
the sensory fibers has been described as occurring predominantly in patients with 
demyelinating lesions distributed along the length of the motor axons (van der 
Meche et aI., 1988a, 1988b, 1989). If within nerve fascicles motor fibers are so 
severely affected that even the axons are damaged without affecting the adjacent 
sensory fibers, this suggests that axonal degeneration is not merely a bystander 
process, but restricted to already affected motor fibers. The paranodal area has 
been shown to be an important area for axon to myelin transport of molecules 
necessary for the assembly of myelin (Oroz, 1979). Likewise it might be assumed 
that the axon is dependent on myelin-axon contact for its normal function. Indeed, 
in experimental models of demyelinating neuropathy it has been demonstrated that 
axonal function is altered after demyelination (Rao et aI., 1981; Oikarinen and 
Kalimo, 1984). 
Severe axonal degeneration is known to carry a bad prognosis (McLeod, 1981; 
Brown and Feasby, 1984; Albers et aI., 1985; Feasby et aI., 1986; Miller et aI., 
1987). Recently, however, attention has been drawn to low CMAPs as a general 
prognostic factor (Comblath et aI., 1988; Winer et aI., 1988). A low CMAP, howe-
ver, can be caused by distal demyelination without a concomitant severe clinical 
course (van der Meche et aI., 1988a, 1988b). In contrast, a relatively high CMAP 
in the initial EMG may later be followed by severe axonal degeneration as shown 
in this study. 
The timing of the EMG is, therefore, of importance. Miller et a1 (1988) (Miller et 
aI., 1988) have suggested, that the ideal time may be 7 days after the nadir is 
reached. This, however, restricts the prognostic value of the CMAP early in the 
disease. 
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Chapter eight 
General discussion 
8.1 Introduction 
The Dutch Guillain-Barre study has been a unique opportunity to study the results 
of electrodiagnostic testing in an early stage of the disease. A clinical follow-up of 
6 months could further substantiate the initial diagnosis and, therefore, the electro-
diagnostic studies may be regarded as having been performed in a group of GBS 
patients diagnosed on the basis of a clinical golden standard, independent of the 
electl'Odiagnostic study itself. For electrodiagnostic testing a rigid and relatively 
extensive protocol was designed. 90% Of the patients had weakness for 14 days or 
less at the first EMG and hence this first EMG can be regarded as a test early in the 
disease. The present study is the first one in which a rigid EMG pl'Otocol has been 
applied in an early stage of exclusively clinically defined GBS. 
8.2 Findings and technical considerations 
Electrodiagnostic abnormalities can be found in an early stage of GBS. At the first 
EMG the DMLs, CMAP amplitudes after distal stimulation and recruitment pat-
terns on maximal voluntary effort showed the highest rate of abnormality. This is 
of great importance in the differential diagnosis of acute flaccid paresis, particu-
larly if myotatic reflexes still persist as occurs occasionally in GBS. In general, the 
findings are in agreement with those found in other studies. 
Parameters thusfar not studied systematically have been drawn from detailed 
analysis of CMAP measurement. Prolongued duration of the CMAP indicates dis-
persion in conduction velocities of individual fibers. This phenomenon is an im-
portant indicator of abnormality, if m-NCV or the DML are within normal ranges. 
As pointed out above, m-NCV and DML critically depend on the fastest fibers, and 
hence do not reflect conduction abnormalities in slower conducting fibers. CMAP 
dispersion in the presence of normal m-NCV and DML is a frequent finding in 
GBS. 
CMAP reduction in a nerve traject is an almost exclusive electrodiagnostic sign of 
conduction block. However, there is much debate about the normal limits of 
CMAP reduction in healthy volunteers. A reduction of 50% has been mentioned as 
an upper limit of normal by some authors. This is in contrast to our experience, as 
is obvious from our reference values, which were collected from healthy volun-
teers. Therefore, we used limits specific for each of the motor nerves. If, however, 
the CMAP amplitude obtained after distal stimulation is already low, it becomes 
meaningless to express CMAP reduction as a percentage as measuring errors may 
vary up to 1 mY. To overcome false signs of conduction block due to the usual 
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measurement inaccuracies, we proposed to use the upper limit of normal or a 
difference of at least I m Vas a limit for abnormal CMAP reduction. CMAP reduc-
tion may also be the result of phase cancellation due to abnormal temporal disper-
sion. This can be separated from pure conduction block if the duration of the 
CMAP is taken into account. Both phenomena, however, are a result of 
demyelination. Therefore, for diagnostic purposes, we applied CMAP reduction re-
gardless of CMAP duration. Obviously, at least two stimulation points are nesse-
cary to show the presence of CMAP reduction. However, usually the most proxi-
mal parts of the nerve trajectory are not accessible for supramaximal surface stimu-
lation, whereas extreme distal stimulation CMAP recording is obscured by stimu-
lus artifact. As a consequence CMAP changes over these most distal and proximal 
stretches can not be detected. This is a major drawback, because notably these sites 
have been suggested to harbour conduction deficits, at least in part of the patients. 
Particularly the low CMAP amplitudes, which occur frequently in an early stage of 
the disease, defy further analysis by standard electrodiagnostic techniques. As a 
consequence it is, as yet, impossible to discriminate electrophysiologically distal 
demyelination from axonal degeneration as a cause of low CMAP amplitudes. 
However, biophysical and immunological arguments exist, which suggest the 
presence of distal conduction block in GBS. 
The present study stresses the importance of sound technical methodology. Particu-
larly CMAP measurement is prone to pitfalls as discussed in chapter 2. In general a 
substantial variability is found among normal individuals, and this may well be the 
reason why CMAP measurement has been neglected so long. Therefore, it is 
important to collect reference values for each laboratory as different electrodes and 
electrode placement lead to different limits of normal. We have shown that, when 
propel' reference values are obtained, and attention is being paid to possible pitfalls, 
reliable and diagnostically inportant conclusions can be derived from CMAP 
analysis. Hence, we suggest, that CMAP measurement (with surface electrodes) is 
routinely performed in every EMG laboratory. 
8.3 Criteria and prognostic value 
We developed criteria jor polyneuropathy and jor demyelination. The effecti-
veness of these criteria was tested in 135 patients with clinically proven GBS. An 
extremely high sensitivity and specificity for GBS patients in an early stage of the 
disease was obtained by requiring a minimal number of abnormal variables in 
more than one nerve. The criteria for demyelination, however, scored less well. 
This may be explained by the patchy localisation of abnormalities throughout the 
nerve and by the fact that testing of CMAP reduction cannot be applied to every 
segment, particularly not the most distal and proximal segments of the peripheral 
nerve. This will probably have caused a serious underestimation of the incidence of 
CMAP reduction. Therefore, lack of fullfilling the criteria does not exclude 
demyelination. Validation of the criteria for polyneuropathy has to be performed in 
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other kinds of polyneuropathy; the sensitivity of criteria for demyelination has to 
be analysed further in patients with motor neuronopathies in the future. 
Among the electrodiagnostic variables analysed, CMAP amplitude and recruitment 
pattern on maximal voluntary effort, turned out to be significant prognostic faclors 
in GBS. However, in individual patients, one has to be careful because many 
patients, in whom low CMAP amplitudes are found, may recover satisfactorily. As 
described, low CMAP amplitudes may reflect conduction block due to demyelina-
tion as well as axonal degeneration. They cannot be separated electrodiagnostical-
ly, but they have very different outcomes. Furthermore, one has to bear in mind, 
that for a function like walking proximal muscles are more important than distal 
muscles which are generally used for CMAP measurement. The important finding, 
that the recruitment pattern in distal muscles has considerable prognostic value, 
would thus suggest an ever more important role for recruitment testing in proximal 
muscles. This has to be evaluated in future studies. 
8.4 Electrophysiological subtypes 
Clinically, GBS is defined as a more or less symmetrical polyneuropathy. Patholo-
gical observations show a variability between patients in the localisation of lesions; 
widespread lesions as well as lesions typically confined to nerve roots and predo-
minant injury of intramuscular nerve twigs, may be discerned. A similar subdivisi-
on has been proposed by electrophysiological studies. Some pathophysiological 
findings have made it likely that parts of peripheral nerves may be differentially 
injured. Furthermore, the usual compression sites may be more vulnerable. At the 
level of the roots, the intramuscular nerve twigs and at the usual compression sites 
it is generally assumed that the blood nerve barrier is either absent or deficient. 
Therefore, these sites are particularly prone to demyelination due to humoral 
factors. Proximal and distal lesions may result in specific electrophysiological 
changes as is summarised in table 22. More diffuse or random lesions result in 
random conduction block. Such diffuse lesions imply breakdown of the bloodnerve 
barrier or threspassing of previously activated T-cells through intact blood nerve 
barrier. 
It would seem attractive to subdivide GBS patients into three groups (proximal, 
diffuse and distal) according to the predominant site of injury (table 22). However, 
both an attempt to categorise patients according to this scheme and a formal cluster 
analysis failed to discern the existence of these simple categories. Therefore, we 
have to conclude to the existence of an electrophysiological continuum. However, 
we do not know whether this continuunl results from the limitations of our electro-
diagnostic parameters or that this continuum is a true reflection of the sum effect of 
underlying pathophysiological factors. It is conceivable that the inherent limitati-
ons of our electrophysiological parameters obscure the possible existence of true 
pathophysiological subgroups in terms of a predominant site of injury. Some of 
these parameters preclude unequivocal interpretation in terms of localisation. 
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Recruitment pattern will always be abnormal irrespective where conduction block 
occurs along the nerve; it is the electrophysiological counterpmi of clinical paresis. 
Table 22. 
predominant site 
prox 
intermediate/diffuse 
distal 
DML m-NCV F-Iat CMAP CMAP pattern 
dist. reduction 
=/1 
DML: distal motor latency; tnMNCV: motor nerve conduction velocity; F-lat: F-Iatency if 
DML and m-NCV are normal; CMAP dist.: CMAP amplitude after distal stimula·tion; 
CMAP dacay: CMAP amplitude reduction after proximal stimulation compared to distal 
stimulation; pattern: recruitment pattern after maximal voluntary effort. 
As pointed out before, DML and NCVs may be quite normal or near normal as 
long as the fastest fibers are spared and are therefore not a very sensitive indicator 
of abnormalities. Moreover predominant distal location of conduction abnormali-
ties will obscure abnormalities occming at more proximal sites. For instance, if 
conduction block is present distally with very low CMAPs, then detection of inter-
mediate conduction block will be very difficult, because below a certain level of 
distal CMAP amplitude further reduction cannot be detected anymore. How distal 
conduction block may defy more proximal demyelination, is nicely illustrated by 
patients that on the [lfst examination show length dependent CMAP reduction, but 
subsequently develop equally low CMAPs for distal as for proximal stimulation. 
An excessive increase of distal conduction block compared to conduction block 
more proximally may be due to a higer vulnerability at the level where the axon 
branches into the terminal twigs and at the transition of myelinated to unmyelina-
ted endings. As a result, in patients with low distal CMAPs from onset onward one 
can not differentiate between axonal degeneration and distal conduction block. Nor 
is it possible to differentiate between axonal degeneration limited to the distal 
motor twigs alone or degeneration throughout the whole nerve. Because of these 
limitations it is not surprising that these electro diagnostic parameters fail to discri-
minate subgroups on a basis of predominant site of nerve injury. 
Therefore in the search for subtypes it would be more appropriate to reverse the 
problem and look whether electrodiagnostic characteristics correlate with any 
clinical, pathological or immunological subtypes of GBS. Such studies are now in 
progress. 
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8.5 Future research 
One of the most important projects in the near future will be the further evaluation 
of the electrodiagnostic criteria. First of all the sensitivity of the criteria for poly-
neuropathy have to be tested in other polyneuropathies like diabetic neuropathy. 
Additionally the specificity of the criteria for primary demyelination have to be 
tested in patients with purely axonal motor neuron disorders. FUlihermore, it is 
desirable to test the effectiveness of the electrodiagnostic criteria presented here, in 
GBS patients less afflicted than the in this study, none of whom were able to walk 
independently at entry. 
Distal demyelination versus axonal degeneration as two causes for a low distal 
CMAP can not be separated with conventional conduction studies. Measurement 
of twitch tensions may possibly differentiate between the two by comparing twitch 
tension after distal nerve stimulation and motor point stimulation. 
Given the prognostic value of recruitment pattern measurements in distal muscles, 
this parameter should be evaluated for proximal muscles, as proximal muscle 
power is perhaps even more correlated with functional outcome. Recruitment 
pattern can easily be performed, whereas proximal muscles are not easily accessi-
ble for conduction studies. 
Finally, the awaited further differentiation of immunological subtypes of GBS 
patients have to be correlated with electrodiagnostic parameters in order to elucida-
te the underlying pathophysiological mechanisms. This may fUliher substantiate 
the as yet uncertain existence of electrodiagnostic subtypes. 
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General summary 
The aim of this study was to describe several aspects of electro diagnostic testing in 
the acute stage of the Guillain-Barre syndrome. 
In chapter one a general description of the Guillain-Barrt! syndrome is given with 
respect to the clinical, pathological and immunological features; additionally the 
therapeutical options are discussed. The design of the Dutch Guillain-Barre trial is 
introduced and the main questions of this electrodiagnostic study are put forward. 
Chapter two describes the electrophysiology of nerve conduction in normal and 
abnormal jibers, and continues with principles and inte/pretation of motor 
conduction studies in patients with polyneuropathy. The importance of CMAP 
analysis in demyelinating polyneuropathy is explained and the technical aspects of 
CMAP maesurements, including the avoidence of pitfalls, is discussed. 
In chapter three the literature concerning electrodiagnostic testing in Guillain-
Barre syndrome is reviewed. Since Lambert's original report in 1960, several 
important electrodiagnostic findings have been reported repeatedly. These include 
the presence oflow CMAP amplitudes early in the disease, which reflect conducti-
on block, as well as conduction slowing somewhat later in the disease. Other 
important esthablished features ifGBS consist of the appearence of axonal degene-
ration and in severe cases "inexcitable motor nerves". However, electrodiagnostic 
studies of GBS often show conflicting results. This may be due to the variability in 
clinical severity, the patchy distribution of lesions, different timing of the studies 
and technical aspects of the electrodiagnostic studies. 
In chapter four the electrodiagnostic jindings and patterns of this study are desci-
bed. 135 Patients were prospectively followed with 3 EMG's. The first EMG was 
performed with a median delay of 6 days after onset of the disease followed by an 
examination one and four weeks later. The distal motor latencies and the CMAPs, 
after distal stimulation of upper limb nerves, were most often abnormal (> 80%). 
Decrease of nerve conduction velocity, abnormal dispersion of the CMAP, abnor-
mal reduction of the CMAP with more proximal stimulation and recruitment 
pattern were abnormal in about half of the patients. For the whole group, the 
abnormal parameters found at the first examination changed little over the second 
and third EMG, the only exeption being the presence of denervation potentials, that 
increased over time. However, in individual patients changes do occur and therefo-
re the EMG at the nadir was found to be most relevant clinically. Subgroup analy-
sis either using a paradigm described before or using a formal cluster analysis did 
not reveal subgroups as an explanation of the observed pathophysiological variabi-
lity. It is concluded that a continuum of pathophysiological abnormalities exists 
and that this may reflect also a spectrum of immune mechanisms variably playing a 
role in the individual patient. 
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Chapter jive describes the development of eiectrodiagnostic criteria for the detec-
tion of polyneuropathy and demyelination. 85% of Guillain-Barre patients fulfilled 
criteria for polyneuropathy in the first EMG (mean time inteval 6 days after onset 
of the disease), whereas none of 45 healthy volunteers did. The sensitivity and 
specificity of these criteria and also the criteria published by others were tested in 
135 Guillain-Barre patients all in an early stage of the disease. They were all 
included in the Dutch Guillain-Barre trial. Different sets of electrodiagnostic 
criteria for polyneuropathy and demyelination have been suggested, but such 
criteria have never been formally tested. We formulated in this study algorithms 
consisting of sets of selected electrodiagnostic parameters, which, individually, are 
generally accepted indicators of abnormality. The proposed criteria for demye-
lination were fulfilled in 60%, 66% and 72%, respectively, in three consecutive 
EMGs, performed within one month of onset; again, this was not the case in any of 
the healthy volunteers. By using criteria published before by others, the sensitivity 
of electrodiagnostic testing was generally considerably lower. Further studies are 
necessary, to test sensitivity and specificity of these criteria in GBS versus other 
polyneuropathies and motor neuropathies. 
In chapter six the prognostic value of electrodiagnostic tests is described. Indepen-
dent locomotion 8 weeks and 6 months after entry were considered to be the outco-
me measures of most clinical value. Electrodiagnostic data obtained one week after 
entry were concluded to be most important for studying prognostic value. This has 
been attributed to the fact that 87% of the patients were at the nadir of their disease 
at that moment. In univariate analysis, CMAP amplitudes of thenar and hypothenar 
muscles obtained after distal and proximal stimulation, as well as the recruitment 
pattern on maximal voluntary effort in all three tested muscles, were significant 
predictors for outcome 8 weeks and 6 months after entry in the study. Motor nerve 
conduction velocity and distal motor latencies of ulnar and median nerves were 
weak predictors of outcome at 8 weeks after entry. In multivariate analysis the 
hypothenar CMAP amplitude on distal stimulation and recruitment pattern of 
abductor digiti minimi muscle both had an independent predictive value for inde-
pendent locomotion 8 weeks after entry. 
Chapter seven describes aspects of severe atOnal degeneration which occasionally 
occurs in Guillain-Barre patients, and often results in permanent functional deficit. 
In order to assess the development of axonal degeneration, a consecutive series of 
42 patients was followed longitudinally using clinical and neurophysiological 
methods. Eight patients were considered to suffer from severe axonal degeneration: 
in these 8 patients denervation potentials were eventually found and at least one 
nerve proved inexcitable. Clinical recovery was slow and incomplete. Five of these 
eight patients initially showed a pronounced conduction block, the physiological 
hallmark of demyelination, before signs of axonal degeneration developed. In the 
remaining three patients, the first evaluation revealed low amplitudes with only 
modest conduction block; this is consistent with predominantly distal demyelina-
tion, but might, alternatively, be explained by primary axonal degeneration. In 
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general we conclude that severe axonal degeneration is likely to be preceeded by 
demyelination. Therefore, at present is not necessary to propose a seperate sub-
group of axonal GBS. Axonal involvement may partly reflect more severe clinical 
course with fulminant demyelination with an excess of bystander axonal degenera-
tion. 
Chapter eight is the general discussion in which also suggestions are made for 
future research. 
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Samenvatting 
Het doel van de dit proefschrift is het beschrijven van de electrodiagnostische 
aspecten van het Guillain Barre syndroom in de acute fase. 
In het eers/e hoofds/uk wordt een algemene beschrijving gegeven van het Guillain-
Barre syndroom, inclusief de klinische, pathologische, immunologische en 
therapeutische aspecten. Tevens wordt het ontwerp van de Nederlandse Guillain-
Barre trial kOli besproken. De belangrijkste electrodiagnostische vraagstellingen 
van deze studie worden gepresenteerd. 
Hoofds/uk !wee beschrijft de electrofysiologie van de zenuwgeleiding in normale 
en abnormale zenuwvezels, ter introdllctie tot de principes en interpretatie van 
motorisch zenuwgeleidingsonderzoek bij patienten met polyneuropathie. De meest 
belangrijke parameter bij onderzoek van polyneuropathieen is de CMAP; de mee-
ste pitfalls kunnen worden voorkomen door het onderzoek nauwgezet uit te voeren. 
In hoofds/uk drie wordt de literatuur betreffende electrodiagnostisch onderzoek van 
het Guillain-Barre syndroom besproken. Sedert de pUblicatie van Lambert, date-
rend uit 1960, zijn veranderingen in verschillende belangrijke electrodiagnostische 
variabelen gerapporteerd: vroeg in de ziekte komt geleidingsblokkade voor, welke 
zich uit in afname van CMAP-amplitudes en, in het algemeen wat later tijdens 
ziekte, geleidingsvertraging. De electrodiagnostische bevindingen zijn in de litera-
tuur echter vaak met elkaa .. in tegenspraak. Mogelijk wordt dit veroorzaakt door de 
variabiliteit van de klinische ernst, de vlekkige verdeling van de afWijkingen in het 
perifere zenuwstelsel, verschillende tijdstippen van onderzoek ten opzichte van het 
ontstaan van de ziekte en door de technische aspecten van het electrodiagnostische 
onderzoek. In de meeste publicaties echter worden geleidingsvertraging, gelei-
dingsblokkade, axonale degeneratie en, in ernstige gevallen, onprikkelbare motori-
sche zenuwen beschouwd als de meest belangrijke electrodiagnostische bevin-
dingen van het Guillain-Barre syndroom. 
In hoofds/uk vier worden de electrodiagnostische bevindingen beschreven. 135 
Guilain-Barre patienten werden longitudinaal met drie EMG's onderzocht. Het 
eerste EMG werd gemiddeld zes dagen na ontstaan van de ziekte verricht, de 
volgende EMG's een week en vier weken na het eerste. De distale motorische 
latentietijden en de CMAP amplituden verkregen na distale stimulatie van armze-
nuwen waren de meest frequente abnormale variabelen (> 80%). Geleidingsvertra-
ging, abnormale dispersie van de CMAP, abnormale reductie van de CMAP ampli-
tude bij meer proximale stimulatie en het aanspanningspatroon waren in 50% van 
de gevallen afwijkend. Voor de gehele groep patienten werden opmerkelijk weinig 
veranderingen vastgesteld in de variabelen gedurende de follow-up van drie 
EMG's; een uitzondering vormde de denervatie activiteit die toenam in de tijd. In 
individuele patienten deden zich wei veranderingen voor; electrodiagnostisch 
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onderzoek vroeg in het nadir verricht is het meest informatief. Onderzoek naar het 
voorkomen van subgroepen of wei gebruik makend van de eerder beschreven 
paradigma, of wei volgens formele cluster-analyse, heeft tot de conclusie geleid, dat 
er een continuUm van pathofysiologische afwijkingen is als uiting van een spec-
trum van immunologische mechanismen, welke in individuele patienten aanwezig 
kunnen zijn. 
In hoofdstuk vijf wordt de constructie van electrodiagnostische criteria voor de 
detectie van polyneuropathie en demyelinisatie beschreven. Vijfentachtig pro cent 
van de Guillain-Barre patienten voldeden aan de criteria voor polyneuropathie in 
het eerste EMG (gemiddeld zes dagen na ontstaan van de ziekte); dit in tegenstel-
ling tot 45 gezonde vrijwilligers. De sensitiviteit en specificiteit van deze criteria 
en ook van de criteria door anderen gepubliceerd, werden in 135 Guillain-Barre 
patienten getest, die in een vroeg stadium van de ziekte verkeerden. Ze maakten 
allen dee I uit van de Nederlandse Guillain-Barre trial. Verschillende sets van 
electrodiagnostische criteria voor polyneuropathie en demyelinisatie zijn voorge-
steld, maar werden niet formeel getest. Wij formuleerden in dit onderzoek algorit-
men, bestaande uit sets van geselecteerde electrodiagnostische parameters, die 
individueel algemeen geaccepteerde maatstaven zijn voor afwijkingen in de ze-
nuwgeleiding. Aan voorgestelde criteria voor demyelinisatie werd voldaan in 60%, 
66% en 72%, respectievelijk in de drie opeenvolgende EMG's, verricht in de eerste 
maand van de ziekte; dit wederom in tegenstelling tot de gezonde vrijwilligers die 
niet voldeden aan de criteria. Toepassing van eerder door anderen gepubliceerde 
criteria resulteerde in lagere sensitiviteit van de electrodiagnostische tests. Verder 
onderzoek is noodzakelijk om de sensitiviteit en specificiteit van deze criteria te 
testen ten opzichte van andere polyneuropathieen en ten opzichte van motorische 
neuropathieen. 
In !wofdstuk zes wordt de prognostische waarde beschreven van electrodiagno-
stisch onderzoek in het Guillain-Barre syndroom. Lopend zonder steun acht weken 
en zes maanden na entry in de trial werden beschouwd als de meest waardevolle 
eindpunten in klinische zin. Electrodiagnostische data verkregen een week na 
entry, werden beschouwd als de meest relevante voor onderzoek naar prognosti-
sche waarde. Dit werd ondersteund door het feit dat 87% van de patienten op dat 
moment in hun klinisch nadir verkeerden. Na univariate analyse bleken CMAP 
amplitudes van thenar en hypothenar verkregen na distale en proxima Ie stimulatie 
zowel als het aanspanningspatroon in aile onderzochte spieren significante predic-
tieve waarde te hebben voor beide eindpunten. Motorische zenuwgeleidingssnelhe-
den en distale motorische latentietijden van armzenuwen, bleken zwakke predictie-
ve waarde te hebben voor het eind op acht weken. Na multivariate analyse bleek de 
hypothenar CMAP amplitude verkregen na distale stimulatie in het aanspannings-
patroon van de musculus abductor digiti minimi beiden onafhankelijke predicitieve 
waarde te hebben voor lopen zonder steun acht weken na entry. 
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In "oofdslllk zeven worden aspecten beschreven van ernstige axonale degeneratie 
die zich soms voordoet in Guillain-Barre patienten, wat vaak blijvende invaliditeit 
tot gevolg heeft. Teneinde de ontwikkeling van axonale degeneratie te kunnen 
vaststellen, werden 42 Guillain-Barre patienten longitudinaal klinisch en electrodi-
agnostisch onderzocht. Acht patienten hadden verschijnselen van ernstige axonale 
degeneratie: denervatie potentialen, tenminste een onprikkelbare zenuw, klinisch 
langzaam en incompleet herste\. Vijf van deze acht patienten hadden aanvankelijk 
uitgesproken geleidingsblokkade, een typisch verschijnsel van demyelinisatie, 
voordat zich tekenen van axonale degeneratie openbaarden. In de overige drie 
patienten werd aanvankelijk lage CMAP amplituden met slechts bescheiden 
geleidingsblokkaden aangetroffen. Dit is in overeenstemming met predominante 
distale demyelinisatie, maar kan in tegenstelling hiermee ook berusten op primaire 
axonale degeneratie. Over het algemeen kan geconcludeerd worden, dat ernstige 
axonale degeneratie voorafgegaan kan worden door demyelinisatie. Daarom is op 
dit moment de veronderstelling van een axonale vorm van het Guillain-Barre 
syndroom als een aparte groep niet houdbaar. Axonale schade kan beschouwd 
worden als bystander-effect van zeer ernstige demyelinisatie. 
Hoofdslllk aclll bevat de algemene discussie, waarin ook suggesties worden gedaan 
voar verder onderzoek. 
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Appendix I: Clinical criteria (Asbury, 1990) 
I. Features Required for Diagnosis 
A. Progressive motor weakness of more than one limb. The degree ranges 
from minimal weakness of the legs, with or without mild ataxia, to total 
paralysis of the muscles of all four extremities and the trunk, bulbar and 
facial paralysis, and external opthamoplegia. 
B. Areflexia (loss of tendon jerks). Universal areflexia is the rule, though 
distal areflexia with definite hyporeflexia of the biceps and knee jerks will 
suffice if other features are consistent. 
II. Features Strongly Supportive of the Diagnosis 
A. Clinical features (ranked in order of importance) 
I. Progression. Symptoms and signs of motor weakness develop rapidly 
but cease to progress by four weeks into the illness. Approximately 50% 
will reach the nadir by two weeks, 80% by three weeks and more than 
90% by four weeks. 
2. Relative symmetry. Symmetry is seldom absolute, but usually, if one 
limb is affected, the opposite is as well. 
3. Mild sensory symptoms or signs. 
4. Cranial nerve involvement. Facial weakness occurs in approximately 
50% and is frequently bilateral. Other cranial nerves may be involved, 
particular innervating the tongue and muscles of deglutition, and some-
times the extra ocular motor nerves. On occasion (less than 5%), the 
neuropathy may begin in the nerves of the extraocular muscles or other 
cranial nerves. 
5. Recovery. It usually begins two to four weeks after progression stops. 
Recovery may be delayed for months. Most patients recover function-
ally. 
6. Autonomic dysfunction. Tachycardia and other arrythmias, postural 
hypotension, hypertension, and vasomotor symptoms, when present, 
support the diagnosis. These findings may fluctuate. Care must be exer-
cised to exclude other bases for these symptoms, such as pulmonary 
embolism. 
7. Absence or fever at the onset of neuritic symptoms. Variants (not 
ranked) 
I. Fever at ontset of neuritic symptoms. 
2. Severe sensory loss with pain. 
3. Progression beyond four weeks. Ocassionally, a patient's disease 
will continue to progress for many weeks longer than four or the 
patient will have a minor relapse. 
4. Cessation of progression without recovery or with major penna-
nent residual deficit remaining. 
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5. Sphincter function. Usually the sphincters are not affected, but 
transient bladder paralysis may occur during evolution of symp-
toms. 
6. Central nervous system involvement. Ordinarily, Guillain-Barn! 
syndrome is thought of a disease of the peripheral nervous system. 
Evidence of central nervous system involvement is controversial. 
In occasional patients, such findings as severe ataxia interpretable 
as cerebellar in origin, dysarthria, extensor plantar responses, and 
ill-defined sensory levels are demonstrable, and these need not 
exclude the diagnosis if other features are typical. 
B. Cerebrospinal fluid features strongly supportive of the diagnosis. 
I. CSF protein. After the first week of symptoms, CSF protein is elevated 
or has been shown to rise on serial lumbar punctures. 
2. CSF cells. Counts of 10 or fewer mononuclear leukocytes/mm' in CSF. 
Variants 
1. No CSF protein rise in the period of one to ten weeks after the onset of 
symptoms (rare). 
2. Counts of II to 50 mononuclear leukocytes/mm' in CSF. 
C. Electrodiagnostic features strongly supportive of the diagnosis. 
Approximately 80% will have evidence of nerve conduction slowing or 
block at some point during the illness. Conduction velocity is usually less 
than 60% of normal, but the process is patchy and not all nerves are affec-
ted. Distal latencies may be increased to as much as three times normal. 
Use ofF-wave responses often gives godd indication of slowing over proxi-
mal portions of nerve trunks and roots. Up to 20% of patients will have 
normal conduction studies. Conduction studies may not become abnormal 
until several weeks into illness. 
III. Features Casting Doubt on the Diagnosis 
1. Marked, persistent asymmetry of weakness. 
2. Persistent bladder or bowel dysfunction. 
3. Bladder or bowel dysfunction at onset. 
4. More than 50 mononuclear leukocytes/mm' in CSF. 
5. Presence of polymorphonuclear leukocytes in CSF. 
6. Sharp sensory level. 
IV. Features That Rule Out the Diagnosis 
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I. A current history of hexacarbon abuse (volatile solvents; n-haxane and me-
thyl n-butyl ketone). This includes paint lacquer vapors or addictive glue 
sniffing. 
2. Abnormal porphyrin metabolism indicating a diagnosis of acute intermit-
tent porphyria. This would manifest as increased excretion of porphobi-
linogen and delta-aminolevulinic acid in the urine. 
3. A history or finding of recent diphtheritic infection, either wound, with or 
without myocarditis. 
4. Features clinically consistent with lead neuropathy (upper limb weaknesws 
with prominent wrist drop; may be asymetrical) and evidence of lead 
intoxication. 
S. The occurence of a purely sensory syndrome. 
6. A definite diagnosis of a condition such as poliomyelitis, botulism, hysteri-
cal paralysis, or toxic neuropathy (e.g., from nitrofurantoin, dapsone, 
organophosphorus compounds), which occasionally may be confused with 
Guillain-Barre syndrome. 
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Appendix II: The electrodiagnostic protocol applied in the Dutch Guillain-
Barre trial 
NERVE CONDUCTION STUDIES 
STIMULATION 
Surface electrodes are to be used for stimulation. Prefered stimulation duration: 
0.3 msec. 
Supramaximal stimulation is obtainted by searching for the optimal site at low 
stimulus strength. Then the stimulus strength is increased to supramaximal 
level. Sometimes a high stimulus strength is needed. 
Minimal distance of stimulation sites proximal and distal over knee and elbow 
> 7 cm.; preferably 10 cm. 
RECORDING 
Motor responses: 
Ag - AgCl electrodes (diam. 9 mm) are used in a tendon-belly montage. 
Position of the indifferent electrodes: 
M.APB and M.ADV: the carpophalangeal joint (1) 
M.EDB: the tarsophalangeal joint (V) 
After positioning the indifferent electrode, the "active" electrode is used to 
search for the optimal position of the searching electrode. This is esthablished 
as soon as: 
the CMAP-amplitude is maximal; 
has the steepest negative deflection; 
has the shortest duration. 
The electrodes have to be fixed properly with adhaesive tape and electrode 
paste. 
SensOlY responses: (antidromic ally evoked) 
Dig. II and Dig. V ring surface electrodes; placed 2,5 cm. apart with the proxi-
mal electrode at the first intraphalangeal joint. 
N.suralis: surface electrodes "Medelec, blue type" with inter-electrode distance 
of 3 cm; placed at the malleolus lateralis; stimulation site 12 cm. proximal 
from recording electrode at the calf. 
F-responses: 
Obtainted from a series of 20 stimuli (cathode in proximal direction). Check 
for the maximal evoked CMAP before and after. 
Filter settings' 
sensory amplitude 
motor amplitude 
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: 10 Hz.- 2 kHz. 
: 2 Hz.-IO kHz. 
Timebase' 
Sensory potentials 
motor potentials 
Amplification: 
: 2 or 5 msec.ldiv. 
: 5 msec.ldiv. 
Such, that the evoked CAP is projected over several screen divisions. 
MEASUREMENT OF PARAMETERS 
CMAP amplitude top-top in mV (± 0,1 mY) 
latency in msec. (± 0, I msec.) 
duration neg. potential above baseline in msec. (± 0,1 msec.) 
CNSAP amplitude top-top in mV (± 0,1 uV) 
latency in msec. (± 0,1 msec.) 
duration of negative part of the potential above baseline in msec. (± 0,1 msec.) 
distances in cm. (± 0,5 cm.) 
TEMPERATURE 
Skin surface temperature of all stimulation and recording sites (± 0.5 ·C). 
All conduction velocities will be corrected for temperature by the coordinating 
centre. 
MYOGRAPHY 
With the concentric needle electrode the muscle has to be tested for: 
recruitment pattern on maximal voluntary effort; 
denervation activity; 
fibrillation and positive sharp waves, rated as follows: ° = not present; + = 
some; ++ = many; +++ = baseline completely occupied. 
motor unit potential characteristics. 
FOLLOW UP: 
First EMG: within two days after randomisation; 
Second EMG: one week after randomisation; 
Third EMG: four weeks after randomisation. 
Nerves 10 be lesled: 
Motor nerves (recording sites between parenthesis). 
Ulnar nerve stimulation; at wrist, distal and proximal of elbow, sulcus bicipita-
lis (M.ADV). 
Median nerve stimulation; at wrist and elbow (M.APB) facultatively: 
Peroneal nerve stimulation; at ankle, distal and proximal of fibular head 
(M.EDB). 
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Sensory nerves (recording sites betwee parenthesis). 
Ulnar nerve stimulation wrist, distal and proximal of elbow, sulcus bicipitalis 
(Dig. V) 
Sural nerve stimulation at calf(ankle). 
F-I'esponses: 
Ulnar and median nerve with stimualtion at the wrist (M. ADV respectively M. 
APB); 
Peroneal nerve with stimulation at ankle (M.EDB). 
Mllscles to be tested electl'omyographically: 
M. APB; M. ADV; M.TA. 
* or the most nearby settings 
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Appendix III: An example of the datasheet 
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Appendix IV: 
The following persons and institutions participated in the Dutch Guillain-Barre 
Study Group. An asterisk indicates those who performed electrodiagnostic testing. 
Co-ordinating center: University Hospital Dijkzigt, Er~smus University, Rotter-
dam. Clinical co-ordinator: R.P. Kleyweg, neurologist.\ E.M.G. co-ordinator: J. 
Meulstee', neurologist. Organisation trial office: R.M. vanlden Hoven. 
Monitoring Commiffee: F.G.A. van der Meche, neurologist, (chairman), H.F.M. 
Busch, neurologist, R.P. Kleyweg, neurologist, M.L. Lee, statistician, 1. Meulstee, 
neurologist, P.I.M. Schmitz, statistician. 
Of her cenfers: ranked according to the number of patients randomised. Acade-
misch Ziekenhuis Groningen, A.E.J. de Jager, T.W. van Weerden'. Academisch 
Ziekenhuis Utrecht, P.L.Oey', J.P. Ter Bruggen. Academisch Medisch Centrum, 
Amsterdam, J. Starn, B.W. Ongerboer de Visser'. De Wever Ziekenhuis, Heerlen, 
C.L. Franke, J.W. Vredeveld'. Westeinde Ziekenhuis, Den Haag, W.F.M. Arts, 
E.J. Jonkman', A.W. de Weerd'. St. Josephziekenhuis, Eindhoven, B.J. van Kaste-
ren'. Academisch Ziekenhuis bij de Vrije Universiteit, Amsterdam, J.J. Heimans, 
C. Pol man, R.P.M. Strijers'. Ver. Ziekenlmizen Ziekenzorg, Enschede, E.M. de 
Vries - Leenders', E.N.H. Jansen. Canis ius-Wilhelmina Ziekenhuis, Nijmegen, 
C.W.G.M. Frenken, W.I.M. Verhagen'. St. Clara Ziekenhuis, Rotterdam, H.1. v.d. 
Brand', H.A.W. Sinnige. Medisch Centrum Alkmaar, J.A. van Leusden'. St. Elisa-
beth Ziekenhuis, Tilburg, A.A.W. Op de Coul, R.L.A.A. Schellens'. St. Ziekenhuis 
Westelijke Mijnstreek, Sittard, J.J.Korten. Ziekenhuis Leijenburg, Den Haag, 
L.G.F. Sinnige, D.L.J. Tavy', A.K. Wattendorf. Academisch Ziekenhuis Maa-
stricht, C.J. Howeler, F. Spaans'. 
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Appendix V: 
Reference values. 
Methods. 
Nerve conduction studies were performed in a warm temperature controlled room 
(30" Celsius), surrounded by a cage of Faraday. All tests were performed using a 
Nicolet Viking type I Myograph. Single supramaximal stimuli were delivered 
using standard surface stimulator electrodes (diameter 5 mm; interelectrode distan-
ce of25 IlUIl) with cathode located distally. Stimuli were delivered supramaximally 
guided by configuration of evoked motor responses, and consisted mostly of 
rectangular pulses of 0.3 msec. and 20 rnA through in constant current stimulator. 
For motor responses, recording electrodes consisted of surface disk electrodes 
(diameter 10 mm), attached to the skin with electrode jelly and adheasive tape. For 
ulnar, median and peroneal nerve abductor digiti quinti (M. ADV.), abductor 
pollicis brevis (M. APB.) and extensor digitorum brevis (M. EDB.) were used, 
respectively. Optimal recording sites of motor responses were searched for careful-
ly, under guidance of the CMAP configuration, such, that a maximal amplitude, a 
steepest possible initial negative deflection and a shortest possible duration of the 
negative patt of the CMAP emerged. 
In each of the 45 volunteers ulnar, median and peroneal nerves were tested. The 
ulnar nerve was stimulated at the wrist and distal of the ulnar sulcus. The median 
nerve was stimulated at the wrist and at the elbow. The peroneal nerve was stimu-
lated at the ankle, distal and proximal of the fibular head. 
Of all motor responses top-top amplitude, the duration and area of the negative 
phase and the onset latency of the CMAP were measured. Ratios of amplitudes, 
duration and areas of motor responses after stimulation of all stimulus sites were 
computed. Distances between stimulation sites and recording sites were measured 
with an accuracy of 5 mm, after which motor nerve conduction velocity was 
measured. All nerve conduction velocities were transformed to a reference 
temperature of 35" Celsius after measuring the skin temperature using a thermo-
couple (Tempcontrol,type 2003) (Geerlings and Mechelse, 1985). 
Minimal latency of f-responses were obtained after 20 trials, under guidance of the 
optimal CMAP after distal stimulation. 
After collection data were fed into a database and the results were analysed using 
"ST A TA" a statistical program for the personal computer. 
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ulnar median peroneal 
DML' 2.2mS. 3.0mS. 4.3 mS. 
m-NCV§ 60 mls. 60 mls. 50 m/s. 
CMAP 15.5 mY. 12.3 mY. 6.0mV. 
amplitude§! 
reduction\! 16% 11% 41 % 
CMAP surface!! 33 mVmS. 29 mVmS. II mVmS. 
reduction\! 11% 8% 34% 
CMAP duration!! 8.1 mS. 7.2mS. 6.7mS. 
increase!! 12% 12% 19% 
F-Iatencyll 32.3 31.2 59.6 
Reference values: 
Upper limits' and lower limits§ based on 5th, respectively 95th percentile values. t 
after distal stimulation; t in the trajectory of forearm respectively lower leg. DML 
and m-NCVs were transformed to a standard temperature of 35° Celsius according 
to Dejesus, 1973 and Geerlings and Mechelse, 1985. 
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